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‘Apart from hypothesis-generating scientific research, a breast cancer 
classification should correlate with clinical outcome of patients or predict 
efficacy to therapy’ 
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A: Anthracycline (doxorubicin)  
AC: Anthracycline (doxorubicin) Cyclophosphamide 
ACC: adenoid cystic carcinoma  
AC-T: Anthracycline (doxorubicin) Cyclophosphamide plus Taxane  
AD: axillary dissection 
ADP: adenosine diphosphate  
AT: Anthracycline (doxorubicin) Taxane  
BLBC: basal-like breast cancer 
CD: cluster of differentiation 
CK: cytokeratin 
CMF: Cyclophosphamide Methotrexate Fluorouracil 
DAB: Diaminobenzidine 
DCIS: ductal carcinoma in situ  
EGFR: epidermal growth factor receptor  
ER: oestrogen receptor 
FDA: United States Food and Drug Administration 
FEC: Fluorouracil Epirubicine Cyclophosphamide  
FISH: fluorescence in situ hybridization 
G:C: gene copy to chromosome ratio 
GEP: gene expression profile 
Gy: gray (unit of absorbed radiation) 
HER2: human epidermal growth factor receptor 2  
HER2:CEP17: HER2 gene to chromosome 17 centromere ratio 
HMW: high molecular weight keratin 
HR: hormone (oestrogen and progesterone) receptor 
IHC: immunohistochemistry 
IRS: immunoreactive score 
ISH: in situ hybridization 
ME: mastectomy  
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MYC: Myc proto-oncogene  
NOS: not otherwise specified  
NPI: Nottingham Prognostic Index 
P53: protein 53 
P63: protein 63 
PARP: Poly (ADP-ribose) polymerase 
pCR: pathologic complete response 
PCR: polymerase chain reaction  
PR: progesterone receptor 
RNA: ribonucleic acid 
RT PCR: reverse transcription polymerase chain reaction  
RT: radiotherapy  
S-100: S-100 protein 
SEER: surveillance, epidemiology and end results 
SERMs: selective oestrogen receptor modulators 
SMA: smooth muscle actin 
SOX2: SRY (sex determining region Y)-box 2 
T: Taxane 
T: tumour (size)  
TDLU: terminal ducto-lobular unit 
TK: tyrosine kinase 
TN: triple negative 
TNBC: triple negative breast carcinoma  
TNM: tumour, node, metastasis (staging system) 
VEGF: vascular endothelial growth factor  
WHO: World Health Organization 









Invasive breast carcinoma is a group of malignant epithelial tumours thought to arise from 
cells of the terminal ducto-lobular units of the breast. These malignancies differ in clinico-
pathologic phenotype, molecular signature and quite possibly, etiopathogenesis. As a 
whole, breast carcinoma is the most common malignancy in women worldwide, accounting 
for 22% of all female cancers. It is also the most common cause of cancer death in women 
worldwide. Incidence varies widely geographically however many reports show that all 
over the world, breast cancer incidence seems to be on the rise. 
Thanks to the implementation of breast cancer screening programs and the introduction of 
specific tailored treatment modalities, a significant decline in mortality has been observed   
in recent years; particularly in the western world. 
A problem is posed by breast cancers that are currently un-classifiable using routine 
prognostic and predictive markers. These so called ‘triple negative’ tumours (owing to their 
lack of expression of ER, PR and HER2) are grouped together despite the clear 
heterogeneity within this category. There is currently no standard approach to management 
of these tumours or any widely accepted evidence-based and clinically relevant way to sub-
classify them. 
Triple negative breast carcinomas are usually associated with poor prognosis and yet 
paradoxically, reports show that they respond very well to neoadjuvant chemotherapy. The 
intense investigative efforts focused on this entity are thus justified and the search for 
morphological and molecular prognostic and predictive markers as well as specific 











2.1. Breast cancer 
 
2.2.1. Breast microanatomy and the cell of origin theory  
The human mammary gland is comprised of a branching network of ducts that end in 
clusters of terminal ducto-lobular units (TDLUs) (1). In the normal breast TDLU, two 
distinct cell layers are identified lining the tubular structures, an inner luminal epithelial 
layer with secretory function and an outer myoepithelial layer adjacent to the basement 
membrane with contractile function (1) (Fig. 1). This layered architecture is found 
throughout the breast – from nipple to terminal lobules (2). Mammary stem cells comprise 
a third group and these cells lack a specific anatomical location; they may be present both 
basally and luminally (2). This third group of cells was discovered when it was found that 
functional TDLUs can be generated after transplanting isolated cells from different parts of 
the mammary gland to cleared mouse mammary fat pads (3). Mammary stem cells give rise 
to both luminal and myoepithelial cells via a series of lineage-restricted intermediaries (4).  
These three different cell types may be distinguished from one another 
immunohistochemically. Luminal cells express low molecular weight keratins such as CK7, 
8, 18 and 19 (3, 5) (Fig. 2). Myoepithelial cells express smooth muscle actin, calponin, S-
100, p63, p-cadherin, CK5/6, CK14 and CD10 (3, 6, 7) (Figs. 3-4). CK5 and CK14 
however, have also been demonstrated in luminal cells (2). Cells that co-express CK14 and 
CK19 are reported to express high levels of stem cell-associated genes (5). Thus, while to 
some extent it is possible to distinguish between these three cell types, there is an overlap in 
the expression of certain proteins.   
It is possible to conclude that the heterogeneity of the cell population comprising the 
normal TDLU contributes to the heterogeneity observed in the epithelial tumours arising 
from the breast; different types of breast carcinomas could develop from different cell 
populations in the TDLU.  This is the basis of the prevailing concept in the field of breast 
cancer research; that different breast cancer subtypes arise from distinct breast epithelial 
cells at varied stages of differentiation that serve as the ‘cell of origin’ (4, 7). To some 
extent results of gene expression profiling did support this theory with the identification of 
luminal and basal subtypes. The differences in subtypes were thought to reflect differences 
in mutation profiles as well as differences in cell of origin (4). It is uncertain as to how 
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closely the genetic profile resembles the phenotypic reality, and more importantly, to what 
extent it affects the course of the disease and patients’ outcome.  
 




Figure 2 CK18 staining cytoplasm of luminal cells of TDLU 
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2.1.2. Epidemiology of breast cancer 
 
Breast carcinoma is the most common malignancy in women worldwide, and the number 
one cause of cancer death in women (8, 9). Yearly, over 1 million new cases are diagnosed 
(8, 10). Less than 1% of breast carcinomas are diagnosed in men (11). Significant 
geographical and racial differences exist in breast cancer incidence, probably largely related 
to environmental and socioeconomic factors (12, 13). The highest age standardized 
incidence rate is recorded in Belgium (109.2 per 100,000) and the lowest rates (as low as 8 
per 100,000) are recorded in African and Asian countries (14).  Japan remains the only 
high-income country showing low incidence rates (15, 16). According to GLOBOCAN data 
from 2008, the Czech Republic ranks 26
th
 in incidence of breast cancer with an age 
standardized rate of 70.9 (17). In most African countries cervical cancer remains the most 
common malignancy in women however in some North African populations, breast cancer 
incidence rates are similar to those of European countries (8). 
 
Trends of breast cancer incidence show dynamic changes and in general, incidence appears 
to be increasing worldwide. Rising incidences are reported in many Asian countries, 
particularly in India, Singapore and Taiwan (18, 19). A further increase in certain 
developing countries is anticipated with increasing life expectancy (19). An exception to 
the general trend of increasing incidence of breast cancer is observed in the United States 
where there has been a decline in incidence from 2002/2003 primarily in women aged 50-
69 years (10).  
 
Breast carcinoma may be diagnosed at any age but the mean age at diagnosis is 56 years 
thus it typically affects postmenopausal women. Over 90% of cases in the Czech Republic 
occur in patients over 50 years of age (17). Mean age at diagnosis however, varies 
geographically; it is lower in developing countries than in Europe and North America. In 
India for example, a majority of cases are diagnosed in premenopausal women with 45 
years being the age at which incidence peaks (20). Also, Saudi women are typically 46-50 
years of age at diagnosis (21). In African countries, breast cancer incidence rates are also 
higher in premenopausal women (22). These observations imply that there is a true genetic 
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influence on breast cancer development. The biology of breast carcinoma also appears to 
vary geographically as hormone receptor positivity in Taiwanese populations appears to be 
associated with younger age (18). In African and Western  
populations however, it is triple negativity and HER2 positivity that are associated with 
young age at diagnosis (18). 
 
Despite the rising incidence, a decline in breast cancer mortality has been observed in many 
high income countries for the past few decades. This improvement is partially due to the 
benefits of early detection offered by national mammographic screening programs and also 
























2.1.3 Classification of breast carcinoma (historical and current approaches) 
 
Histopathology 
Traditionally breast cancer is classified based on histological appearance. The World Health 
Organization Classification of Tumours recognizes 31 different histological subtypes of 
invasive breast carcinoma (Table 1) (15). Invasive ductal carcinoma NOS (not otherwise 
specified) is by far the most common subtype of breast carcinoma, accounting for up to 
75% of cases (23), followed by lobular carcinoma comprising 5-15% of invasive breast 
tumours (15). The other ’special’ histological types are rare however significant as some of 
them are associated with particular patterns of clinical behaviour and prognosis. Medullary 
carcinoma for example is associated with excellent prognosis despite its aggressive 
histological appearance (24) and adenoid cystic carcinoma in the breast, unlike its head and 
neck counterpart is also associated with good prognosis (25, 26). 
After a morphologic type is assigned to a tumour, grading must be done to assess the degree 
of differentiation as histological subtype alone is a poor predictor of biological behaviour 
and a wide spectrum of differentiation exists, particularly for ductal carcinomas, ranging 
from very well differentiated tumours that closely resemble benign breast tissue to 
dedifferentiated malignancies. Grade is recognized as a powerful prognostic factor as 
studies show a significant association between grade and survival in invasive breast cancer 
(15). It is considered to be one of the strongest prognostic factors in operable breast cancer 
(27). Low grade tumours are associated with low recurrence risk, high grade tumours with 
high risk of recurrence, and prediction of outcome for intermediate or moderately 
differentiated tumours is more ambiguous (27).  
The Nottingham combined histological grading system (also known as the Nottingham or 
the Elston-Ellis modification of the Scarff-Bloom-Richardson grading system) is the most 
widely used grading system for breast cancer (28, 29, 30). There is an international 
consensus that the Nottingham grading system should be the gold standard for breast cancer 
grading (28). Tubule formation, nuclear pleomorphism and mitotic activity are taken in to 





Table 1 WHO histological classification of breast carcinoma (15)  
Malignant Epithelial Tumours of the Breast  
Invasive ductal carcinoma, not otherwise specified 
     Mixed type carcinoma 
     Pleomorphic carcinoma  
     Carcinoma with osteoclastic giant cells 
     Carcinoma with choriocarcinomatous features 






Invasive lobular carcinoma 8520/3 
Tubular carcinoma 8211/3 
Invasive cribriform carcinoma 8201/3 
Medullary carcinoma  8510/3 
Mucinous carcinoma and other tumours with abundant mucin 
     Mucinous carcinoma 
     Cystadenocarcinoma and columnar cell mucinous carcinoma  






     Solid neuroendocrine carcinoma 
     Atypical carcinoid tumour 
     Small cell / oat cell carcinoma 






Invasive papillary carcinoma 8503/3 
Invasive micropapillary carcinoma 8507/3 
Apocrine carcinoma  8401/3 
Metaplastic carcinomas 
      Pure epithelial metaplastic carcinomas 
          Squamous cell carcinoma 
          Adenocarcinoma with spindle cell metaplasia  
          Adenosquamous carcinoma 









     Mixed epithelial/mesenchymal metaplastic carcinomas 8575/3 
Lipid-rich carcinoma 8314/3 
Secretory carcinoma 8502/3 
Oncocytic carcinoma  8290/3 
Adenoid cystic carcinoma  8200/3 
Acinic cell carcinoma 8550/3 
Glycogen-rich clear cell carcinoma 8315/3 
Sebaceous carcinoma 8410/3 





Table 2 Assessment of histological grade in breast carcinomas (15) 
Feature Score 
Tubule and gland formation 
  Majority of tumour (>75%) 
  Moderate degree (10-75%) 






  Small, regular uniform cells 
  Moderate increase in size and variability 










Grade 1 – well differentiated 3-5 points 
Grade 2 – moderately differentiated 6-7 points 




TNM Stage  
The TNM classification system (edited by the International Union against Cancer) is used 
to indicate anatomical extent of disease (31). It is the most widely used staging system for 
malignant disease (32). The classification takes into account size of the invasive component 
of the primary tumour, its relationship to surrounding structures and/or its specific features 
e.g. skin ulceration and presence of tumour cells in dermal lymphatic vessels (inflammatory 
carcinoma) (T), regional lymph node status (N) and presence of distant metastasis (M) 
(Table 3). The information provided by staging helps direct treatment and is of prognostic 
value (33). Figure 5 shows distribution of breast carcinoma by stage for women diagnosed 
in the Czech Republic (17).  
 
Table 3 TNM classification for breast cancer (15) 
Primary tumour (T) 
TX Primary tumour cannot be assessed 
T0 No evidence of primary tumour 
Tis Carcinoma in situ 
Tis 
(DCIS) 
Ductal carcinoma in situ 
Tis 
(LCIS) 
Lobular carcinoma in situ 
Tis 
(Paget) 
Paget disease of the nipple with no tumour in the underlying breast parenchyma.  
T1 Tumour ≤ 20 mm in greatest dimension 
T1mi Tumour ≤ 1 mm in greatest dimension 
T1a Tumour > 1 mm but ≤ 5 mm in greatest dimension 
T1b Tumour > 5 mm but ≤ 10 mm in greatest dimension 
T1c Tumour > 10 mm but ≤ 20 mm in greatest dimension 
T2 Tumour > 20 mm but ≤ 50 mm in greatest dimension 
T3 Tumour > 50 mm in greatest dimension 
T4 Tumour of any size with direct extension to the chest wall and/or to the skin 
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(ulceration or skin nodules) 
T4a Extension to chest wall, not including only pectoralis muscle adherence/invasion 
T4b Ulceration and/or oedema (including peau d’orange) of the skin and/or satellite 
nodules in ipsilateral breast 
T4c Both T4a and T4b, above 
T4d Inflammatory carcinoma 
Regional lymph nodes (N) 
pNX Regional lymph nodes cannot be assessed  
pN0 No regional lymph node metastasis identified histologically.  
pN1 Micrometastases; or metastases in 1-3 axillary lymph nodes and/or in internal 
mammary nodes, with metastases detected by sentinel lymph node biopsy but 
not clinically detected 
pN1mi Micrometastases (> 0.2 mm and/or > 200 cells, but none > 2.0 mm) 
pN1a Metastases in 1-3 axillary lymph nodes (at least 1 metastasis > 2.0 mm) 
pN1b Metastases in internal mammary nodes, with micrometastases or 
macrometastases detected by sentinel lymph node biopsy but not clinically 
detected 
pN1c Metastases in 1-3 axillary lymph nodes and in internal mammary lymph nodes, 
with micrometastases or macrometastases detected by sentinel lymph node 
biopsy but not clinically detected 
pN2 Metastases in 4-9 axillary lymph nodes or in clinically detected internal 
mammary lymph nodes in the absence of axillary lymph node metastases 
pN2a Metastases in 4-9 axillary lymph nodes (at least 1 tumour deposit > 2.0 mm) 
pN2b Metastases in clinically detected, internal mammary lymph nodes in the absence 
of axillary lymph node metastases 
pN3 Metastases in ≥ 10 ipsilateral axillary lymph nodes; or in infraclavicular lymph 
nodes; or in clinically detected, ipsilateral internal mammary lymph nodes in the 
presence of ≥ 1 positive axillary lymph node; or in > 3 axillary lymph nodes with 
clinically negative, microscopic metastasis in internal mammary lymph nodes; or 
in ipsilateral supraclavicular lymph nodes 
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pN3a Metastases in ≥ 10 axillary lymph nodes (at least 1 tumour deposit > 2.0 mm); or 
metastases to the infraclavicular (level III axillary lymph) nodes 
pN3b Metastases in clinically detected, ipsilateral internal mammary lymph nodes in 
the presence of ≥ 1 positive axillary lymph nodes; or in > 3 axillary lymph nodes 
and in internal mammary lymph nodes, with micrometastases or 
macrometastases detected by sentinel lymph node biopsy but not clinically 
detected 
pN3c Metastases in ipsilateral supraclavicular lymph nodes 
Distant metastasis (M) 
M0 No clinical or radiographic evidence of distant metastasis 
M1 Distant detectable metastases as determined by classic clinical and radiographic 




Table 4 Anatomic stage (prognostic) groups (15) 
Stage T N M 
0 Tis N0 M0 
IA T1 N0 M0 
IB T0 N1mi M0 
 T1 N1mi M0 
IIA T0 N1 M0 
 T1 N1 M0 
 T2 N0 M0 
IIB T2 N1 M0 
 T3 N0 M0 
IIIA T0 N2 M0 
 T1 N2 M0 
 T2 N2 M0 
 T3 N1 M0 
 T3 N2 M0 
IIIB T4 N0 M0 
 T4 N1 M0 
 T4 N2 M0 
IIIC Any T N3 M0 

























A landmark study by Perou et al in 2000 concluded that all breast tumours belonged to one 
of four intrinsic subtypes based on results of gene-expression profiling; Luminal/ER+, 
HER2, basal-like and normal breast like (34). These intrinsic subtypes were thought to 
represent distinct entities with diverse behaviour that could be identified using 
immunohistochemical surrogates (Fig. 6) (10, 35, 39). The differences in subtypes were 
thought to reflect differences in mutation profiles as well as differences in cell of origin (4). 
Of particular interest was the basal-like phenotype as it seemed to correspond with the 
immunohistochemically determined triple negative phenotype. At the 12
th
 St Gallen 
International Breast Cancer conference the intrinsic subtypes were reclassified as luminal 
A, luminal B (HER2 negative), luminal B (HER2 positive), HER2 positive (non-luminal) 
and triple negative according to therapeutic options (35). At the 2013 St Gallen consensus 
conference a majority of the panel voted against multi-gene expression array profiling as a 
requirement for subtype definition (36).  
  
Despite the fact that the conclusions drawn from the Perou study were premature and 
incomplete, it led to a revolution in breast cancer research resulting in the development of 
new cDNA gene-expression based tests that predict recurrence risk.  Currently available on 
the market are MammaPrint (Agendia Inc., CA and Amsterdam), Oncotype DX (Genomic 
Health, Inc., CA), the Rotterdam signature and PAM50 (37). So far, only MammaPrint has 
United States Food and Drug Administration (FDA) approval however, Oncotype DX is the 
most widely used clinical gene expression assay in the United States (37). Two trials for 
determining the efficacy of both Oncotype DX and MammaPrint (Trial Assigning 
Individualized Options For Treatment (TAILORx) and Microarray in Lymph node-
Negative Disease may Avoid Chemotherapy (MINDACT) respectively) are currently on-
going and full results are unavailable (38). The first data from the TAILORx are expected 





























(ER+, PR+, HER2-) 
Luminal B  
(ER+, PR+, HER2+) 
HER2  
(ER-, PR-, HER2+) 
Basal-like  




2.1.4. Predictive and Prognostic Markers 
  
There is no single marker variable that adequately predicts outcome in breast cancer. A 
predictive marker predicts response to a particular type of therapy while a prognostic 
marker gives an estimation of clinical outcome in untreated patients (40, 41). Good 
prognosis would indicate that adjuvant systemic therapy may be unnecessary while poor 
prognosis is an indication for aggressive post-surgical systemic therapy (42).  
 
Nottingham Prognostic Index (NPI) 
NPI is a tool for stratifying prognosis in breast cancer patients (Table 5) (42, 43). In routine 
clinical practice, lymph node status, tumour size and histological grade are the strongest 
prognostic indicators in operable breast cancer (44). NPI combines these three prognostic 
factors, known to be independently associated with survival in order to produce a stronger 
predictor of outcome than any of the three alone (43, 45). NPI has been shown to predict 
long term survival in breast cancer patients and its reliability has been validated in several 
studies in its native Nottingham and around the world (40, 42, 44). In combination with 
predictive factors such as hormone receptor and HER2 status as well as individual patient 
needs and wishes, NPI can be used to select patients for adjuvant therapy (42).   
 
Nottingham Prognostic Index = Lymph node stage (1-3) + Histological grade (1-3) + 
Tumour size (cm) x 0.2 
 




3.41-4.4 Moderate 1 
4.41-5.4 Moderate 2 
5.41-6.4 Poor 




Oestrogen and progesterone (hormone) receptors (ER and PR) 
Approximately 75% of breast carcinomas express oestrogen receptors (45). Progesterone 
receptor expression is found in 55-65% of all breast carcinomas is thought to indicate a 
functioning ER pathway (45). ER+/PR+ tumours respond better to hormonal therapy than 
ER+/PR- tumours (45).  
Hormone receptors (HR) are proven to be strong prognostic factors as patients with ER and 
PR expressing tumours are associated with the best outcomes with or without anti-
hormonal therapy (46). According to the results of the SEER program, since 1990, women 
with ER+ tumours have experienced greater declines in breast cancer mortality than those 
with ER- tumours (47). Despite having lower growth rate than ER- tumours, ER+ tumours 
do not have lower metastatic potential (15).  Mortality rate for HR+ tumours appears to 
remain constant over time from diagnosis while for HR- tumours the rate is high for the 
first 3-5 years and then it declines (45).  
In our practice at the Fingerland Department of Pathology, we perform a semi-quantitative 
immunohistochemical assessment of hormone receptor status. An immunoreactive score 
(IRS) of 0-12 is assigned by assessing intensity of nuclear staining and percentage of 
positive cells (Table 6) (48). 
 
IRS = intensity score x percentage score 
 
Table 6 Components of IRS system for immunohistochemical detection of oestrogen and progesterone 
receptors in breast cancer (48) 
Intensity Score   
 
Percentage Score  
Negative                 0  0 0 
Slight           1  ≤10 1 
Moderate  2  11-50 2 
Strong  3  51-80 3 






Human epidermal growth factor receptor (HER2) 
HER2 is a transmembrane receptor kinase that belongs to the same family of receptors as 
epidermal growth factor receptor (EGFR). There is no known ligand for HER2 however the 
receptor is the preferred molecule for dimerization with other members of the ERB family 
upon activation (49). Some authors report that up to 25% of all breast carcinomas 
overexpress HER2 (50-54). More recent, studies particularly in European populations, 
show that the incidence is lower than previously thought (55, 56). HER2 positive tumours 
are more aggressive than HER2 negative tumours and are more frequent in younger women 
(57). Overexpression of HER2 has been associated with poor clinical outcome in patients 
with axillary lymph node metastasis but not in patients with negative nodes (40). 
Overexpression also predicts positive response to HER2 targeted therapy (50). Despite the 
fact that HER2 positivity indicates poorer prognosis, treatment with trastuzumab, a 
recombinant humanized monoclonal antibody against HER2, appears to eliminate the 
differences in outcome (46, 58).  
HER2 is routinely evaluated immunohistochemically and by in situ hybridization.  
Patients with tumours with positive HER2 staining or with HER2 gene amplification (≥ six 
copies of HER2 gene per cell or HER2:CEP17 ≥2.2) are candidates for trastuzumab 
treatment (Table 7) (49).  
 
Table 7 HER2 testing in breast cancer (49) 
Staining pattern Score HER2 staining 
assessment 
Reflex HER2 in situ 
hybridization 
No membrane staining observed 0 Negative No 
Faint partial staining of the 
membrane in any proportion of 
cancer cells 
1+ Negative No  
Weak to moderate complete 
staining of the membrane in 
>10% cancer cells 
2+ Equivocal Yes 
Strong, complete staining of the 
membrane in >10% cancer cells 





The p53 gene is recognized as a tumour suppressor gene and loss of function mutations are 
associated with development of varied malignancies (59, 60). P53 mutations are the most 
frequently observed mutations in carcinomas however the precise mechanism of wild-type 
p53 function is still not fully understood (59). Normal p53 may induce apoptosis or cell 
cycle arrest. Mutant p53 is more stable than wild-type p53 and it has a longer half-life (59, 
61). It can therefore be more easily detected by immunohistochemistry. Mutations in p53 
gene however may not be the only factors leading to p53 stability; it is possible that other 
genetic alterations in different loci may be responsible, in some cases, for prolonging p53 
half-life (60). Immunohistochemical p53 overexpression is seen in neoplastic but not in 
normal breast tissue (59). Up to 54% of breast carcinomas are reported to show 
immunohistochemical p53 expression (59). 
Aberrations of the p53 family of transcription factors have been reported to be predictive of 
response to chemotherapy (41, 62). Some studies show that mutations in the TP53 gene are 
associated with chemoresistance however there are high inconsistencies across studies (62, 
63). Bidard et al suggest that this is because molecular subclasses are not taken into account 
(64). They showed that p53 immunostaining is associated with a trend for higher rates of 
pCR in TNBC (64). For triple negative breast carcinomas Biganzoli et al suggest that p53 
expression is associated with poor outcome (61). Pollner et al however failed to 
demonstrate a statistically significant association between p53 expression and survival (59).    
 
Ki-67  
Proliferation is one of the strongest prognosticators in node-negative breast cancer (65). Ki-
67 is a non-histone nuclear protein that can be detected in nearly all phases of the cell cycle 
but not in resting cells; it is a well-established marker of cell proliferation (15, 29, 66). The 
number of immunohistochemically Ki-67 positive cells present in tumours may be used to 
classify patients as good or poor survivors (15, 27). Aleskandarany et al showed that using 
a cut-off point of 10% positively stained tumour cells, Ki-67 expression could be used to 
classify grade 2 breast carcinomas into two distinct subgroups with different outcome (27).  
A measurement of Ki-67 during/after neoadjuvant therapy also appears to be strongly 
predictive of long-term outcome (67). Aside from being a prognostic marker, Ki-67 also 
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predicts response to endocrine therapy and neoadjuvant chemotherapy (45, 68). Studies 
have shown that adjuvant chemotherapy is significantly beneficial to patients with rapidly 
proliferating tumours but not to patients with slowly proliferating tumours (65). 
It has been suggested that Ki-67 as a marker of proliferation should be used to distinguish 
between luminal A and luminal B subtypes (36, 69).  However Ki-67 is not included in 
current clinical decision making because of a lack of clarity on how the measurements 
should influence clinical decisions (66). This is partially due to issues with quality control 
and assurance (65). Additionally various investigators have used different cut-off points for 
Ki-67 assessment (10%, 14%, 20%) (27, 66, 68). Also, some Ki-67 positive nuclei may not 
survive the cell cycle thus the prognostic value of the Ki-67 index may be blurred (65).  
Despite these limitations, immunohistochemical detection of Ki-67 is still considered to be 
a robust cost effective diagnostic tool that provides useful prognostic information and may 
be useful in planning therapy (27). 




MammaPrint is an RNA based gene-expression prognostic tool that is used to guide 
adjuvant treatment decisions. It was developed based on the Amsterdam 70-gene expression 
profile that was shown to be a powerful predictor of outcome in young breast cancer 
patients (70). MammaPrint helps to identify patients that do not need adjuvant 
chemotherapy and can be spared the toxic side effects and financial burden (71). A 70-gene 
profile is analysed in fresh frozen tumour samples. The testing is performed by the 
manufacturers, Agendia Inc., CA and Amsterdam, (71). The assessment classifies tumours 
as having either poor prognostic signatures with high risk of recurrence or good prognostic 
signatures with low risk of recurrence. Straver et al preformed a study on 167 patients with 
stage I and II breast carcinoma (72). They showed that patients with poor prognostic 
signatures were more likely to achieve a pathologic complete response to chemotherapy 
than those with good prognostic signature. All the triple negative tumours analysed had 
poor prognostic signatures. 
MammaPrint was not accepted by the St. Gallen 2011 international breast cancer consensus 
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panel for clinical decision-making (69). Only a minority of the 2013 St Gallen panellists 
(25%) thought that the 70 gene signature would predict chemotherapy response (36). 
 
Oncotype DX 
Oncotype DX is a 21-gene profile assay that uses RT PCR in formalin-fixed paraffin-
embedded tissue. It is the most frequently used gene expression profile (GEP) in the United 
States (38). It predicts the likelihood of recurrence in node negative ER+ breast cancer. 
Though the assay works independently of nodal status, it appears to be useful only in 
patients with 3 or fewer positive nodes (73). It uses a recurrence score to stratify patients 
into 3 groups; those with high risk, intermediate risk and low risk. Patients categorized as 
low risk will be recommended for endocrine therapy alone (73). The patients with low risk 
recurrence can avoid adjuvant chemotherapy that they do not need. 
The St. Gallen 2011 international breast cancer consensus panel considered Oncotype DX 
to be potentially useful for clinical decision making (69). A majority of the St Gallen panel 




All the factors discussed above form the basis for determining adjuvant therapy for patients 
with breast cancer. The predictive markers currently used are able to identify patients that 
will not respond to certain treatment (negative predictive value) but their ability to identify 
patients that will respond (positive predictive value) is suboptimal (45).  
Isolated knowledge of the individual prognostic markers provides limited information on 
tumour biology. For this reason a combinatorial approach is employed nowadays for 
assessing prognosis and guiding patient management. Still, patients with similar clinico-
pathologic features may show varied outcomes and may respond differently to therapy (71). 
This justifies the on-going intensive search for better predictive and prognostic markers for 






2.1.5 Treatment options for breast cancer  
 
Locoregional treatment 
Surgical treatment for breast cancer is determined for each woman on an individual basis 
(74). For early stage breast cancer, breast conserving surgery followed by irradiation has 
replaced modified radical mastectomy as the preferred treatment option (74, 75). 
Mastectomy may be performed after neoadjuvant chemotherapy of stage III tumours, in 
cases of previous breast irradiation or when clear surgical margins cannot be secured (74). 
The standard technique for postoperative radiotherapy following breast conserving therapy 
is percutaneous irradiation of the entire breast (45-50 Gy) followed by a tumour bed boost 
(76). Routine post-mastectomy RT is endorsed for patients with more than 3 involved nodes 
(69). Post-mastectomy RT is not supported for large (T>2) node-negative tumours (69).  
 
Adjuvant and neoadjuvant (primary) chemotherapy  
Early studies showed increased proliferation in metastatic deposits after resection of the 
primary tumour. It was also observed that preoperative administration of cyclophosphamide 
resulted in maximum decrease in proliferation of cancer cells. These findings provided 
rationale for use of primary chemotherapy for non-metastatic breast cancer (77). Clinical 
evaluation of tumour size remains the gold standard assessing patient suitability for 
neoadjuvant chemotherapy (57). Neoadjuvant chemotherapy is not recommended for low-
proliferating and in highly endocrine-responsive disease (69). Adjuvant systemic therapy 
greatly improves survival in women with both lymph node-positive and lymph node-
negative breast cancer (Table 8). It is recommended for patients with stage IB-IIIB disease 
(78). Standard adjuvant chemotherapy regimens can be used in the neoadjuvant setting and 
anti-HER2 agents should be added for HER2 overexpressing tumours (69).   
TNBCs have been reported to be more sensitive to anthracycline (adriamycine/doxorubicin) 
based neoadjuvant chemotherapy than hormone receptor positive tumours (79). Basal-like 
breast carcinomas (BLBCs) have also been shown to have higher sensitivity to 




Table 8 Preferred agents for adjuvant chemotherapy in different breast cancer subtypes (69) 
Subtype Recommendation 
Luminal A No preference 
Luminal B Anthracyclines and taxanes 
TNBC Cyclophosphamide  
Basal-like Anthracyclines and taxanes 
 
 
Targeted therapy  
Knowledge of the biology of breast cancer has expanded greatly in the last few decades. A 
better understanding of the uniqueness of each tumour leads to a shift from a ‘one size fits 
all’ approach to a more elegant and personalized approach to oncological treatment. The 
lessons learnt about some key pathways involved in breast cancer development and 
progression have enabled the development of agents that specifically target these pathways. 
Some of the agents have already become part of standard care while others are not yet 
approved for use in clinical practice though they have shown some efficacy. Tyrosine 
kinase inhibitors, angiogenesis inhibitors and agents that interfere with DNA repair are 
examples of such novel therapeutics. Oestrogen focused and anti-HER2 therapies are now 
standard components of breast cancer care (81).  
 
Endocrine therapy is the first and oldest form of targeted therapy for breast carcinoma (69). 
Indeed it is the first type of targeted therapy used for any type of cancer. Tamoxifen is a 
non-steroidal anti-oestrogen that started out as a failed contraceptive (82). It belongs to the 
group of selective oestrogen receptor modulators (SERMs) (82). It targets ER+ tumours by 
blocking oestrogen-stimulated growth at the oestrogen receptor (82). Aromatase inhibitors 
such as letrozol suppress oestrogen synthesis, reducing systemic oestrogen levels. For 
premenopausal patients tamoxifen alone is considered to be standard treatment. For cases in 
which tamoxifen is contraindicated, ovarian function suppression with aromatase inhibitors 
is the preferred therapeutic option. Tamoxifen use has been linked to endometrial cancer, 





Trastuzumab is a humanized murine IgG monoclonal antibody that targets the extracellular 
domain of HER2 (49, 57, 58, 83). The mechanism of its action is not fully understood 
however it appears to inhibit DNA repair and induce apoptosis (83). Trastuzumab has been 
shown to reduce signalling through the P13K/Akt and Ras/Raf/MEK/MAPK pathways; it 
has also been suggested that it may promote antibody-dependent cellular cytotoxicity (83). 
In 1998 it was approved by the FDA as first part of line treatment for metastatic HER2+ 
breast carcinoma (58, 84).  
In a study on women with metastatic breast cancer, Dawood et al showed that trastuzumab 
improves the prognostic outcome of women with HER2+ breast cancer beyond that of 
HER2- disease (58). Lapatinib, which gained FDA approval in 2007, is a small molecule 
tyrosine kinase (TK) inhibitor that has been shown to cause remissions in patients with 
HER2+ tumours that are resistant to trastuzumab (58). It selectively binds to both HER2 
and EGFR intracellularly to prevent phosphorylation of pathways which activate cell 
proliferation survival (84). Diarrhoea, neutropenia and liver dysfunction are the common 
adverse effects of lapatinib therapy (84). Dual HER2-targeting therapy (trastuzumab plus 
TK inhibitor) is not currently accepted as a therapeutic option for HER2+ disease (69). 
Pertuzumab is a recombinant humanized monoclonal antibody that prevents HER2 
dimerization thus it inhibits multiple HER signalling pathways (85). Pertuzumab, in 
combination with docetaxel and trastuzumab, is recognized as part of the preferred first-line 
treatment for patients with metastatic HER2+ breast cancer (85).   
 
Poly (ADP-ribose) polymerase (PARP) is an enzyme essential for base excision repair for 
single-strand DNA breaks (7). PARP inhibitors such as olaparib and iniparib target the base 
excision repair pathway of single-stranded DNA. The use of olaparib, an oral PARP 
inhibitor for treatment of breast cancer (locally advanced or metastatic) in women carrying 
a BRCA1 or BRCA2 mutation is associated with a high (41%) response rate (39). 
 
Bevacizumab is a vascular endothelial growth factor (VEGF) inhibitor. VEGF is a key 
mediator of angiogenesis which is required for tumour growth, invasion and metastasis 
(86). Bevacizumab is reported to improve progression-free survival in patients with 
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metastatic TNBC when administered in combination with paclitaxel (39, 87). Despite this 
observation, there is no clear signal that bevacizumab has any special properties in TNBC 
compared with other subtypes of breast cancer (88).  Large trials investigating bevacizumab 
in TNBC are still on-going however it is currently not recommended by the FDA for 
treatment of metastatic breast cancer despite having previously been granted approval (89).    
 
EGFR can be targeted using monoclonal antibodies (cetuximab, panitumumab) which 
target the extracellular domain of the EGFR receptor or with tyrosine kinase inhibitors 
(TKIs) such as erlotinib, gefitinib or afatinib (78, 90, 91). A randomized phase II trial 
testing cetuximab in combination with carboplatin in stage IV TNBC showed low levels of 
response to platinum plus cetuximab and uncommon response to cetuximab alone (92). In 
this study, EGFR pathway analysis revealed that cetuximab blocked expression of the 
EGFR pathway in only a minority of cases (92).    




















2.2 Triple negative breast cancer (TNBC) 
 
Triple negative breast cancer by definition is a diagnosis of exclusion. It includes all 
primary epithelial breast malignancies that do not overexpress HER2 and are negative for 
hormone (oestrogen and progesterone) receptors (87). They account for 10-17% of all 
breast carcinomas (34, 35, 93-96). Some authors report incidences of up to 24% (38). This 
discrepancy could be explained by the varying cut-offs for assessing ER, PR and HER2 
status (97, 98). As of now, no clear evidence-based definition of triple negativity exists. 
Triple negativity is strongly associated with BRCA mutations. Approximately 70% of 
breast cancers in people carrying a germline BRCA1 mutation are triple negative (99). 
Women with triple negative (TN) tumours are shown to be younger than women with 
hormone receptor positive tumours (100). TNBCs are thought to be more common in young 
women (<50 years of age) and in women of African, Hispanic and South East Asian origin 
(94, 100). An American population based case-control study showed that women with TN 
tumours are also more likely to be obese, of lower socioeconomic status and likely to have 
experienced menarche at a younger age than women with hormone receptor positive 
tumours or controls (100). Young age at first full-term pregnancy and black race were also 
shown to be associated with TN phenotype (100). 
This group of malignancies is morphologically, immunophenotypically and biologically 
heterogeneous (87, 101). In general triple negative breast carcinomas are thought to be 
more aggressive with worse outcome than other immunophenotypic subtypes (87). They 
are considered to have bad prognosis with a high risk of death in the first 5 years following 
therapy but reduced late recurrences/deaths (96). Relapse of TNBC usually occurs within 
the first three years of the breast cancer diagnosis (10, 93, 102). The liver, lungs and central 
nervous system are common metastatic sites (94). TNBCs are unlikely to respond to 
hormonal or anti-HER2 therapy thus the only standard systemic treatment option available 
is conventional chemotherapy (87, 101).  
The morphological features associated with TN ductal NOS carcinoma are high nuclear 
grade, marked cellular pleomorphism, lack of tubule formation, scant stromal content, 
tumour necrosis, pushing borders of invasion, lymphoplasmacytic inflammatory infiltrate 
and, central acellularity (2, 35). There are however, certain rare morphological subtypes of 
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breast cancer with specific histological features and predictable clinical behaviour that are 
associated with triple negativity.  
One example is adenoid cystic carcinoma (ACC). ACC has a distinct biphasic pattern 
consisting of true glandular spaces lined by epithelial cells and pseudocystic spaces lined 
by myoepithelial cells. Unlike ACC in the head and neck, primary breast ACC has excellent 
prognosis (26). Medullary carcinomas, which are also associated with triple negativity, 
whether typical or atypical, have better outcome than high grade ductal carcinomas NOS 
(103). Medullary carcinomas account for 1-7% of all breast carcinomas (15) and tend to 
occur in younger women (94, 104). 5 morphologic features define this subtype: syncytial 
architecture, absence of glandular structures, moderate to intensive lymphoplasmacytic 
infiltrate, high nuclear grade and complete microscopic circumscription (15, 105, 106). 
Tumours that do not fulfil all 5 of the histologic diagnostic criteria are sometimes referred 
to as atypical medullary carcinomas (103). Unlike with other morphological subtypes of 
breast cancer, ER positivity in medullary carcinomas is associated with poorer overall 
survival (94). 
Secretory carcinoma of the breast, originally referred to as juvenile carcinoma, is a very 
rare histological subtype of breast cancer (0.15% of all breast cancers) (15, 107). It is the 
most common type of breast cancer seen in children however the disease is most frequent 
in young adults (108). It is a low grade, generally well circumscribed tumour composed of 
round to polygonal cells producing intra and extracellular PAS and alcian blue positive 
secretory material (15, 107, 108, 109).  
Metaplastic carcinomas of the breast are epithelial malignancies with partial or complete 
transformation to a non-glandular epithelial or mesenchymal cell type (110). They are 
classified as matrix producing carcinomas, squamous cell carcinomas, spindle cell 
carcinomas, carcinosarcomas or metaplastic carcinomas with osteoclastic giant cells (110). 
Unlike other special histological types of triple negative breast cancer, metaplastic 
carcinomas appear to be inherently aggressive and associated with poorer prognosis than 
invasive ductal carcinoma NOS. Over 50 % of the patients develop local or distant 
metastasis within 5 years.  Jung et al reported poorer 5-year DFS for metaplastic breast 




Thanks to the discoveries from gene expression profile studies, there has been a great 
interest in identifying the so-called basal phenotype in TNBC and more recently, the 
claudin-low phenotype. The claudin-low phenotype was first identified by Herschkowitz et 
al in 2007 as a distinct molecular subtype of human breast cancer (111). Claudin-low 
tumours express mesenchymal genes with low gene expression of e-cadherin and tight 
junction proteins claudins 3, 4 and 7 (112, 113). They show inconsistent expression of basal 
cytokeratins, low expression of HER2 and luminal markers, and do not show high 
expression of proliferation genes (113).  
Claudins belong to a family of tight junction proteins which are critical for epithelial cell 
polarity and maintaining the differentiated state of epithelial cells (114). 
Immunohistochemical studies on claudins in breast cancer have yielded results that are 
rather difficult to interpret.  Claudins 3 and 4 appear to be overexpressed in breast cancer 
while claudins 1 and 7 appear to be down-regulated or completely absent (114). Claudin 1 
positivity however has been reported to be more common in ER- than in ER+ tumours 
(114).  Lanigan et al found that high claudin-4 expression was associated with poor 
prognosis and high tumour grade (115). Kulka et al demonstrated high levels of claudin-4 
expression in basal-like breast carcinomas (116). The same research group observed loss of 
claudin-4 expression in well differentiated breast carcinomas (117). 
 
The most widely accepted IHC definition for basal-like carcinoma is that proposed by 
Nielsen et al; any CK5/6 and/or EGFR positivity in TNBC (98). To the best of our 
knowledge there are no widely accepted immunohistochemical criteria for the identification 
of the claudin-low phenotype. Both basal and claudin-low subtypes are associated with 
poor outcomes (113) and a tendency to metastasize to the brain and lungs (118). 
 
The basal-like phenotype is perhaps more attractive to study in TNBC because it may be 
reliably identified immunohistochemically and not only is EGFR a potential prognostic 
marker, it is also a very attractive molecule for biological therapy.  About 60% of TNBCs 
are reported to express EGFR (93) however the role this plays in breast cancer development 




2.3. Basal-like breast carcinoma  
 
‘Basal-like’ is one of the four intrinsic subtypes of breast cancer initially proposed by Perou 
et al based on their cDNA microarray study of 43 different benign and malignant breast 
tissues (36 infiltrating ductal carcinomas, 2 lobular carcinomas, 1 DCIS, 1 fibroadenoma 
and 3 normal breast samples) (34).  In their sample, there was a group of 6 tumours that 
highly expressed genes characteristic for breast basal epithelial cells, including CK5, CK17, 
integrinβ4 and laminin (34). All six of these tumours showed positive 
immunohistochemical staining for CK5/6 and/or CK17. This was proof of the ‘basal-ness’ 
of this group of tumours. The basal-like tumours were ER- and appeared to be distinct from 
the HER2+ tumours (34).  It appeared that TNBC could be the immunohistochemical 
surrogate of BLBC.   Since the 2000 Perou publication, numerous authors have emphasized 
that TNBC and BLBC are not the same but that an overlap exists between the two groups 
of tumours. ER expression has been reported in 5-45% of BLBCs and HER2 expression in 
14% (119). Foulkes et al define basal-like breast cancer as follows ‘a subtype of breast 
cancer defined by unsupervised analysis of microarray gene-expression data… 
characterized by the absence of or low levels of expression of estrogen receptors, very low 
prevalence of HER2 overexpression, and expression of genes usually found in the basal or 
myoepithelial cells of the human breast’ (101). Thus like TNBC, BLBC appears to be a 
heterogeneous group of breast malignancies.   
The significance of the basal-like subtype is controversial. While most studies have 
indicated that basal-like breast carcinomas have poor prognosis, not all of them have done 
so (120).  Jumppanen et al. suggest that there is no difference in survival between the basal 
and non-basal hormone receptor negative tumours (121). 
BLBCs are usually ductal NOS carcinomas with solid architecture and high nuclear and 
histological grade (3, 120). Geographic necrosis, ribbon-like architecture and prominent 
lymphocytic infiltrate are common histological features of this group (6, 35, 120, 122). 
95% of medullary carcinomas are basal-like (3). Use of oral contraceptives in women <40 
years old, younger age at menarche, Hispanic ethnicity, abdominal obesity and metabolic 
syndrome are amongst the risk factors associated with BLBC (122).  
The basal-like phenotype is common in patients with germline BRCA1 mutations (98).  
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GEP for identification of intrinsic subtypes is only performed in research settings. The tests 
are expensive and complex for routine diagnostic purposes however the information they 
yield may be useful in assessing prognosis. These issues are solved by finding 
immunohistochemical surrogates for identifying the prognostically significant subtypes of 
breast carcinoma. High molecular weight keratins CK5, CK5/6, CK14, and CK 17 have 
been used in various combinations by different investigators for identifying the basal-like 
phenotype in TNBC (119). Besides the ‘gold standard’ immunohistochemical definition of 
BLBC proposed by Nielsen et al, other investigators have suggested and used different 
criteria for identifying the basal-like phenotype. Rakha et al proposed using a cut off of 
10% positively staining tumour cells for evaluating CK5/6 (123). Cakir et al suggest adding 
vimentin and CK14 to the panel in order to identify basal-like breast carcinomas (35). 
Cserni and Bori used expression of EGFR, CK5, CK14 or p63 to identify the basal 
phenotype in TNBC (124). 
Poorly differentiated basal-like carcinomas have been shown to overexpress certain 
embryonic stem cell genes such as SOX2 and MYC (4). The stem cell has been presumed 
to be the cell of origin for basal-like carcinomas however studies have shown that the basal-
like group bears a striking resemblance to luminal progenitor cells (4). This suggests that 
‘luminal progenitor’ subtype is a more apt description for HR-/HER2-/CK5/6 and/or 
EGFR+ carcinomas than basal-like.  
An immunohistochemical study of 6 secretory carcinomas carried out by Lae at el 
concluded that secretory carcinomas are low grade triple negative breast carcinomas 
belonging to the basal-like spectrum (107). Other reports have demonstrated expression of 
basal cytokeratins (CK5/6, CK14 and CK17) as well as EGFR in secretory carcinomas 
(125). Unlike for other basal-like breast tumours, prognosis for patients with secretory 
carcinoma is good (107, 109). It is somewhat paradoxical that these tumours with apparent 
features of luminal differentiation simultaneously express markers of basal differentiation. 







2.4. Germ-line BRCA1 mutations and TNBC/BLBC 
 
The BRCA1 gene located on chromosome 17 is known to be involved in a large proportion 
of people with inherited susceptibility to breast and ovarian malignancies (15). BRCA1-
related tumours account for approximately 5% of all breast cancers (87). BRCA1 mutations 
may be suspected in breast cancer cases that are diagnosed at a young age (15).  
It has been suggested that BRCA1 may be involved in breast epithelial cell differentiation. 
It appears to be required for transition from an ER- progenitor to an ER+ progenitor (7).  
As such, the inactivation of BRCA1 would give rise to tumours with stem cell-like features 
(122). BRCA1 related tumours are high grade malignancies with high mitotic activity, 
syncytial growth pattern, pushing margins, geographic necrosis and prominent lymphocytic 
infiltrates (3, 120). Also, when large, they are less likely to be lymph node positive than 
non-BRCA1 related tumours (126). The histological characteristics of BRCA1 related 
breast cancers are strikingly similar to those of basal-like or triple negative breast cancer, as 
described above. Indeed, 75% of breast cancers in women with germ-line BRCA1 
mutations are basal-like and/or TN (39). Even in basal-like tumours without BRCA1 
mutations, there is evidence of dysfunction in the BRCA1 pathway (39, 122).  
Foulkes et al performed a study in order to determine whether BRCA1-related breast 
cancers were more likely to express a basal epithelial phenotype than non-BRCA1 related 
cancers (120). They found that BRCA1 related breast cancers are statistically significantly 
associated with expression of basal cytokeratin (CK5/6). It is reported that even partial 
suppression of BRCA1 function in human mammary epithelial cell cultures can induce 
EGFR expression and an increase in cancer stem-like cells (127). 
The breast carcinomas arising in patients with BRCA1 mutations have defective DNA 
double strand break repair mechanisms thus therapeutic agents that target DNA repair 
pathways such as olaparib are effective in their treatment (39, 122). 










2.5. Basal Markers 
 
2.5.1. P-Cadherin (CDH3) 
P (placental)-cadherin belongs to the family of classical cadherins which are 
transmembrane glycoproteins that serve as calcium-dependent cell-cell adhesion molecules 
(128, 129). To this group also belong CDH1/e (epithelial)-cadherin, CDH2/n (neuronal)-
cadherin and CDH4/r (retinal)-cadherin (129). The intracellular domains of cadherins are 
linked to actin cytoskeletons via cytoplasmic catenins. The cadherin-catenin complexes and 
the pathways they control play important roles in regulation of cell growth, differentiation, 
motility and survival. They are also essential for maintaining the structural integrity of 
epithelial tissues (130). In stratified and pseudo stratified epithelium, its expression is 
restricted to the basal layers (130, 131).  
P-cadherin alterations are detected in many human tumours. Its exact role in carcinogenesis 
is uncertain as the consequences of its expression vary depending on tumour cell model and 
context (128, 129). In melanoma and colorectal carcinoma cell lines, p-cadherin seems to 
act as an anti-invasive and anti-migration molecule. In in vitro breast cancer models as well 
as in urothelial, pancreatic and cholangiocarcinoma cell lines however, p-cadherin seems to 
behave as an oncogene and its over-expression is associated with single cell motility and 
invasion capacity (129). 
P-cadherin is expressed in normal breast myoepithelial cells and it shows no significant 
cross-reactivity with luminal epithelial cells, stromal myofibroblasts or vessels (129, 130). 
It also appears to be expressed by breast stem cells (130).  It is associated with poorly 
differentiated carcinomas and with triple negativity (129, 130). P-cadherin is expressed in 
20-40% of invasive carcinomas and in 25% of DCIS. Liu et al showed that p-cadherin 
expression is associated with decreased disease-free interval and overall survival (128).  
P-cadherin expression is strongly associated with BRCA1 mutations and is an important 









Protein 63 (p63) is a member of the p53 family comprising p53, p63 and p73. The human 
gene encodes at least six different isoforms (132). The transactivating isoform has a similar 
function to p53 while the N-isoform inhibits the transcriptional activation of p53 (133).  
Its translation products are crucial for the maintenance of a stem cell population in human 
epithelium (132, 134). It is expressed by basal and intermediate cells of squamous 
epithelium and urothelium (132, 134). In normal breast tissue, p63 expression is usually 
limited to myoepithelial cells and mammary stem cells (135) (Table 9).  It is considered to 
be a highly specific marker for the nuclei of myoepithelial cells (132, 136) .Luminal cell 
expression however has been described in papillary lesions as well as in nuclei and 
cytoplasm of epithelial cells showing secretory differentiation (133). Secretory carcinomas 
which are usually triple-negative, have been shown to have either cytoplasmic or nuclear 
p63 positivity (133).  
The role of p63 in breast carcinoma is unclear and the protein has been studied as both an 
oncogene and a tumour suppressor gene. In an RT PCR study of human bladder cancer cell 
lines and primary tumours, Choi et al showed that muscle invasive tumours expressing p63 
had worse prognosis than those not expressing the marker (134).  
In the breast, however the ΔN isoform of p63 has been shown to be a tumour suppressor 
(135).   
Hanker et al suggest that p63 is a positive predictive marker for response to endocrine 
therapy and a marker of good prognosis (132).  A study by Rocca et al examined the 
significance of p63 expression in tumour response to chemotherapy. They reported a high 
rate of pCR in p63 positive tumours after primary chemotherapy with cisplatin only 
(without anthracyclins) (62). 
They suggest that cisplatin-based regimens are more effective in p63 positive tumours than 




CD10, also known as enkephalinase, is a zinc dependent membrane associated neutral 
endopeptidase that cleaves signalling peptides (4, 137). It is expressed on a variety of 
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normal cell types including fibroblasts and granulocytes, and it has been shown to be 
expressed during B-lymphocyte maturation at early-B and pre-B lymphoblastic stages 
(137). In the breast, it is strongly expressed in normal myoepithelial cells and those 
associated with benign proliferations (5, 138). While it stains stromal fibroblasts, vessels 
are negative for the marker (138).  
Aside from being a myoepithelial marker, CD10 has been used to identify breast stem cells 
(4, 137, 139). CD10 is involved in mammary gland development, controlling cell growth 
and differentiation and it also maintains and regulates the mammary stem cell population 
(137, 139).  
Expression of CD10 may be observed in the stroma of invasive breast carcinoma. It has 
been suggested that this feature is associated with poor prognosis (137, 140). CD10 
expression is also seen in a subset of mammary sarcomas (138, 141). 
CD10 staining has been observed in a variety of other tumours. Positive staining may be a 
marker of good prognosis in cervical and non-small cell lung carcinomas while in 
melanomas and colorectal carcinomas it is an indicator of poor prognosis (137).  
  
2.5.4. CK5 and CK6 (detected using anti-cytokeratin 5/6 antibody)  
Anti-cytokeratin 5/6 is a mouse monoclonal primary antibody that detects cytokeratins 5 
and 6. CK5 is a basal cytokeratin expressed by mammary myoepithelial cells (131). It is 
also expressed by multipotent progenitor epithelial cells in the breast located between the 
basal and luminal layers in normal ducts (142). It has been suggested that tumours 
expressing CK5 originate from these progenitor cells. CK6 is expressed by proliferating 
squamous epithelial cells.  
CK5/6 is the most commonly used CK marker for identifying basal-like breast carcinoma 
(98, 120, 143). Foulkes et al showed that expression of CK5/6 is statistically significantly 
associated with BRCA1-related breast cancers (143, 144). The same group showed that 
CK5/6 positive tumours are likely to be larger, high grade tumours occurring in younger 
women (143). In their study, they showed that CK5/6 expressing tumours were associated 
with worse disease-specific outcome than CK5/6 non-expressing tumours. In an 
immunohistochemical study of 105 cases of TNBC, Sutton et al showed that in CK5/6 
positive TNBCs, intratumoral expression of CK5/6 was significantly higher in the node-
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positive group than in the node-negative group (94).  However, the difference in expression 
of CK5/6 between the node-negative and distant metastasis groups did not achieve 
statistical significance (p=0.057). Nielsen et al suggest that CK5/6 is a basal-like breast 
cancer specific marker (98). 
 
2.5.5. Other high molecular weight cytokeratins (detected using 34βE12/HMW 
antibody) 
34βE12 is a mouse monoclonal primary antibody that recognizes CKs 1, 5, 10 and 14. It is 
used for detection of basal epithelial cells such as basal cells in the prostate or of stratified 
squamous epithelium (145). In the breast, CK5 and CK14 are expressed by basal epithelial 
cells, including mammary myoepithelial cells (131). Both cytokeratins are widely used as 
markers of the basal phenotype (124, 146). The fact that HMW is able to detect multiple 
high molecular weight cytokeratins makes it a possible marker of BLBC. Bori and Cserni 
showed that absence of HMW staining had a 94% negative predictive value regarding the 
basal-like phenotype (124). 
An immunohistochemical microarray study with 58 TNBCs showed that expression of 
34βE12 is an independent predictor of survival (146). The authors suggested that 34βE12 
identifies a subset of TNBCs associated with better prognosis.  
 
2.5.6. Epidermal growth factor receptor (EGFR)/HER1/ErbB1 
 
The EGFR gene is located on chromosome 7 (147, 148). Its protein product EGFR belongs 
to the superfamily of transmembrane receptors with intrinsic protein tyrosine kinase 
activity (149). It is widely expressed on many cell types including all epithelial and stromal 
cells (149). In polarized epithelial cells, it is localized to the basolateral aspects, allowing 
for epithelial-stromal communication (149). EGFR is the sole or largely predominant 
receptor for several distinct ligands including EGF, TGF-alpha, amphiregulin and heparin-
binging EGF (149). EGFR activation triggers numerous signalling pathways and the 
biological responses to activation include apoptosis, proliferation, migration and 
dedifferentiation depending on a number of extracellular factors (127, 149, 150). EGFR 
signalling is thought to play an important role in organ repair (149).  In order to be 
functionally active, it must undergo dimerization, which is possible with all members of the 
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HER family.  
EGFR and other members of the erbB family play important roles in tumour cell survival 
and proliferation (151). EGFR inhibition in both in vivo and in vitro models has been 
shown to induce apoptosis and inhibit angiogenesis and cell proliferation (152). 
EGFR gene amplification and/or protein overexpression is seen in a wide variety of solid 
tumours and in some cases (e.g. non-small cell lung carcinoma, colorectal carcinoma), is 
associated with advanced stage and unfavourable prognosis (153). Amongst the therapeutic 
agents that target EGFR are monoclonal antibodies against the extracellular domain of the 
receptor (e.g. cetuximab, panitumumab and matuzumab) and low molecular weight tyrosine 
kinase inhibitors (e.g. erlotinib, gefitinib, lapatinib and afatinib) (127). 
 
EGFR overexpression has been described in 8-36% (146) of breast carcinomas and is 
correlated with poor prognosis. In triple negative breast carcinomas, the proportion is even 
higher (in up to 60%)  (148, 154, 155). High rates of EGFR positivity are also observed in 
metaplastic carcinomas and mammary NOS-type sarcomas (139). 
While the consequences of EGFR expression in breast cancer are still largely unknown, 
EGFR remains an attractive candidate for targeted biological therapy, provided a suitable 
method for patient selection can be devised. As at now, EGFR inhibitors do not appear to be 















2.6. Luminal marker - CK18 
CK 18 is an acidic cytokeratin that is a major cytoskeletal component of cells of simple 
epithelia (156). In the breast it is expressed only by luminal/ductal epithelial cells (2, 7).  
Some studies report that CK18 expression is reduced in metastatic breast cancers (157). 
Additionally, CK18 expression is also shown to be lacking in a subset of micrometastatic 
tumour cells present in the bone marrow (157). In a 1458 case microarray study, CK18 loss 
was associated with high tumour grade, high mitotic index and large tumour size (157). 
Down-regulation of CK18 is more frequent in ductal than in lobular carcinomas (157).  
CK18 has been shown to be a prognostic indicator of both overall survival and cancer-
specific survival. Buhler et al showed that high expression of CK18 in tumour cells is 













 Luminal cells  Myoepithelial cells Stem/progenitor 
cells 
CK5/6 +/- + + 
CD10 - + + 
P63 - + + 
CK18 + - +/- 
CK14 +/- + + 
p-cadherin - + + 
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3. Objectives  
 
The main objectives of this work were twofold: 
 
 To identify clear prognostically significant immunophenotypic  and morphological 
subtypes within the triple negative group of breast carcinomas using 
immunohistochemical detection of p-cadherin, p63, CD10, CK5/6, EGFR, HMW, 





 To study EGFR in triple negative breast carcinoma using in situ hybridization for 
detection of gene or chromosomal numerical abnormalities that may be of 



























4. Materials and Methods 
 
 
Patients and tumour specimens  
A retrospective search was performed in the archives of The Fingerland Department of 
Pathology for all cases of pre-treatment invasive breast carcinoma diagnosed between 2005 
and 2008, inclusive.  From the pathology reports, the following information was obtained 
in each case: patient age at diagnosis, tumour type and grade as well as 
immunohistochemically detected expression of ER, PR, Ki-67 and p53. HER2 status was 
also noted.  Hormone receptor negativity was defined as immunoreactive score (IRS) = 0 
for oestrogen and progesterone receptors – i. e. no immunohistochemical staining for ER 
and PR. HER score = 0, 1+ or 2+ non-amplified by FISH or dual-ISH (HER2 gene-
chromosome 17 ratio < 2) was taken to be negative. Positive nuclear staining for Ki-67 in 
≥20% of tumour cells was used to define high proliferative activity. p53 positivity was 
defined as nuclear staining in ≥ 50% tumour cells. Based on ER, PR and HER2 status we 
identified 4 immunophenotypic subtypes: ER and/or PR+ and HER2- (HR+/HER2-), ER 
and/or PR+ and HER2+ (HR+/HER2+), ER and PR- and HER2+ (HR-/HER2+) and ER 
and PR-, HER2- (HR-/HER2-).  
For subsequent analysis we included only TN cases with sufficient archive material for 
further investigations and for which adequate follow up clinical data were available. The 
archived biopsy material was obtained in form of both core needle biopsies and resection 
specimens. For each case, one representative formalin-fixed paraffin-embedded tissue 
block was selected. Consultation cases as well as tumours in patients with a known history 
of prior breast carcinoma were all excluded. Also patients with distant metastases at the 
time of diagnosis were excluded from our final analysis.  
A total of 52 formalin-fixed paraffin-embedded tissue blocks from 52 distinct patients 
fulfilled all the selection criteria and were included in the immunohistochemical and in situ 







Nottingham Prognostic Index (modified) 
As NPI is not routinely used in our institution, for each case NPI was calculated (NPI= 
lymph node stage + histological grade + tumour size x 0.2) and based on the results patients 
were assigned to one of five prognostic groups as described in section 2.1.4. For patients 
that did not receive neoadjuvant therapy, tumour size and lymph node stage were 
determined from diagnostic pathology reports. For those that did receive neoadjuvant 
therapy, tumour size and lymph node stage were taken from diagnostic mammography 
reports. In 2 cases a cT stage was assigned without noting exact tumour size. For these 
cases we estimated NPI based on the limits of tumour size given for the particular T stage. 
To simplify our classification, and because of our small sample size we combined the 
‘excellent’ and ‘good’ groups, ‘moderate 1’ and ‘moderate 2’ groups and finally, we 
combined ‘poor’ and ‘very poor’ groups. Thus we classified our tumours as having good, 
moderate or poor prognosis.  
 
Morphologic Assessment 
The following parameters were assessed in the selected TN tumours from the original 
haematoxylin eosin slides used for diagnosis.  
- nuclear atypia (degree of atypia scored on a scale of 1-4) 
- tumour borders (pushing vs. infiltrating) 
- tumour architecture (syncytial vs. non-syncytial)  
- intra/peritumoural lymphoplasmacytic infiltrate 
- presence/absence of central acellular zone (scar or necrosis) 
- presence/absence of tumour necrosis 
- presence/absence of in situ component 
- stromal features 








Immunohistochemical Assay and Assessment   
Indirect immunohistochemical staining for p-cadherin, p63, CD10, HMW, CK5/6, EGFR 
and CK18 were performed in all cases. Characteristics of the monoclonal antibodies used 
are shown in table 10. Manual staining was performed for p-cadherin as described in table 
11. For the rest of the antibodies, staining was performed using the fully automated 
BenchMark ULTRA platform (Ventana, Arizona, USA). Diaminobenzidine (DAB) was the 
chromogen used in all cases. 
 
Table 10 Details of antibodies used 
Antibody Manufacturer Clone Dilution 
P-cadherin Vector laboratories 56C1 1:25 
TP63 Ventana 4A4 original 
CD10 Novocastra 56C6 1:10 
CK5/6 DAKO D5/16B4 1:100 
HMW DAKO 34βE12 1:25 
CK18 DAKO DC10 1:50 
EGFR DAKO pharmDx™ kit --- 
 
Table 11 Staining technique for p-cadherin 
  
1. Deparaffinization  Xylene 3x10min, 96% alcohol 2x5 min, 70%   
alcohol 5min  
2. Rinse in distilled water 
3. Antigen retrieval  Citrate buffer pH6, peroxide 10min 
4. Rinse in distilled water  
5. Application of primary antibody    60 min   
6. Application of EnVision ™+ Dual Link 
(Dako)  
30 min  
7. DAB  (1ml DAB buffer + 1 drop DAB chromogen) 5 min  
8. Rinse in distilled water  
9. Haematoxylin staining  1 min 




Immunohistochemical staining evaluation 
All specimens were assessed by light microscopy without knowledge of the case histories.  
A semi-quantitative method was used to assess the immunohistochemical stains.  
 
P-cadherin: Any cytoplasmic membrane staining was considered positive. A score from 0-
3 was assigned in each case based on intensity of staining.   
p63: Any nuclear or cytoplasmic staining was considered to be positive, percentage of 
positive tumour cells was recorded. Percentage of positive cells was scored as follows 1 
(<10%), 2 (≥10%, <50%), and 3 (≥50)  
CD10: Any cytoplasmic staining was considered positive, percentage of positive tumour 
cells was recorded. Percentage of positive cells was scored as follows 1 (<10%), 2 (≥10%, 
<50%), and 3 (≥50)  
CK5/6: Any cytoplasmic staining was considered positive. A score from 0-3 was assigned 
in each case based on intensity of staining.  Additionally, percentage of positive tumour 
cells was recorded. Percentage of positive cells was scored as follows 1 (<10%), 2 (≥10%, 
<50%), and 3 (≥50)  
 EGFR: A semi-quantitative method for scoring EGFR expression was used employing a 
combination of staining intensity and percentage of positive tumour cells. Only cytoplasmic 
membrane staining was considered as positive. Intensity was graded on three levels – 1 
(low), 2 (moderate) and 3 (high). Percentage of positive cells was scored as follows 1 
(<10%), 2 (11-50%), 3 (51-80%) and 4 (>80%). A combination of these two parameters 
yielded a final EGFR score of 0-12.  
CK18: Any cytoplasmic staining was considered positive. A score from 0-3 was assigned in 
each case based on intensity of staining.  Additionally, percentage of positive tumour cells 
was recorded. For classification we considered percentage of positively stained cells as 
described by Woelfe et al (157) i.e. normal expression: ≥90% stained tumour cells, partial 
loss of CK18 expression: <90% stained tumour cells, and complete loss of CK18.  
HMW: Any cytoplasmic staining was considered positive. A score from 0-3 was assigned 





Immunophenotypic classification  
Based on expression of the above mentioned markers, we classified the tumours as having 
basal, luminal or luminal progenitor differentiation.  
Basal differentiation was defined as expression of any of the following markers – p-
cadherin, p63, CD10, EGFR, CK5/6 and HMW, without expression of CK18. 
Luminal differentiation was defined as expression of CK18 without expression of any of 
the following markers – p-cadherin, p63, CD10, EGFR, CK5/6 and HMW 
Luminal progenitor differentiation was defined as co-expression of CK18 with any of the 
following markers – p-cadherin, p63, CD10, EGFR, CK5/6 and HMW. 
 
 
Dual ISH Assay and Evaluation  
Dual in situ hybridization for detection of EGFR gene and chromosome 7 was performed in 
all cases. We used a dual colour staining technique for visualization of the EGFR gene and 
chromosome 7 centromere; with Ventana Silver in situ hybridization (SISH) detection kit 
for the EGFR gene and Ventana Alk Phos Red ISH detection kit for chromosome 7 
centromere.  
After deparaffinization of tissue sections (as shown in table 11), automated staining was 
performed using the BenchMark ULTRA platform (Ventana, Arizona, USA).    
For each case, the numbers of copies of EGFR gene (black signals) and chromosome 7 (red 
signals) were counted and recorded in 40 different tumour cell nuclei. The average number 
of copies of the gene and chromosome for each case was recorded and the gene-
chromosome copy (G:C) ratio was calculated and interpreted as follows;  
G:C < 1.8 - no amplification of EGFR gene 
1.8 < G:C < 2.2 - borderline amplification of EGFR gene 
2.2 < G:C < 5.0 - EGFR gene amplification 








Clinical charts for all patients were reviewed. From these, we recorded type of treatment 
(neoadjuvant or adjuvant chemotherapy, radiotherapy, surgical therapy), progression free 
survival  
(in months), overall survival (in months) and outcome at the end of the follow-up period.  
Five possible outcomes were recognized; 
1.) Disease free (no sign of breast malignancy) 
2.) Locoregional residual disease (presence of residual primary tumour or regional lymph 
node metastasis) 
3.) Recurrence (metachronous breast cancer in ipsilateral or contralateral breast) 
4.) Distant metastasis  
5.) Death (death from breast/non-breast cancer related causes) 
 
For our final analysis only those that were disease free at the end of the follow-up period 
were considered to have good outcome. All the others (locoregional residual disease, 
metachronous breast cancer, distant metastases and death) were collectively viewed as 




Statistical analysis was performed using Microsoft Excel (for basic descriptive statistics 
and graph construction). Fisher’s exact test was employed for determining associations 
between our selected prognostic markers, tumour characteristics and survival data. P-values 
<0.05 were considered to be statistically significant. Results were assessed and interpreted 













One thousand and forty nine (1049) primary invasive breast carcinomas (excluding 
consultation cases) were diagnosed at The Fingerland Department of Pathology between 
2005 and 2008 (inclusive), including 3 carcinomas diagnosed in men. Most of the patients 
(809/1049; 77%) had HR+/HER2- tumours. The 2
nd
 largest group was the TN group 
accounting for 12% (128/1049) of all carcinomas followed by the HR+/HER2+ group 
(64/1049; 6%). The smallest immunophentypic subgroup was the HR-/HER2+ group which 
comprised only 48 patients (5%).  
 
The average age at diagnosis for all patients was 61 years (median: 61; range 26-96), for 
the TN patients it was 57 years (median: 58; range: 28-91) and for the non-TN patients 61 
years. When the non-TN patients were further separated into the pre-defined 
immunophenotypic subtypes, it was observed that the HR+/HER2- patients were the oldest 
at diagnosis (average 62 years) followed by the HR-/HER2+ patients (average 58 years) 
(Table 12). The youngest patients (average 55 years) were those with HR+/HER2+ positive 
tumours. 
 
Histological grade varied with immunophenotype (Fig. 7). None of the TN carcinomas 
were well differentiated. A majority of them (72%; 96/133) were poorly differentiated. Of 
the 4 immunophenotypic subtypes we identified, the TN group had the highest percentage 
of poorly differentiated (grade 3) tumours. All of the well differentiated carcinomas (grade 
1) were HR positive. Only two of these also showed HER2 overexpression.  
 
Table 12 Age and immunophenotype of all patients diagnosed with breast cancer at the Fingerland 
Department of Pathology (2005-2008) 
 HR+/HER2- HR+/HER2+ HR-/HER2- (TN) HR-/HER2+ 
Average 62 55 57 59 
Median 62 57 58 58 
Range 26-96 27-82 30-91 36-89 
52 
 

















































Characteristics of Study Set 
 
Fifty-two patients with TNBC fulfilled all our selection criteria and were included in the 
study set for further investigation. Basic clinico-pathologic features of these cases are 
shown in table 13. The average age of our patients at diagnosis was 55 years (range: 28-84 
years). Three of the patients were found to be carriers of BRCA mutations; BRCA status of 
all the other patients was unknown. 
The group as a whole was characterized by high tumour grade, high proliferative activity, 
and p53 positivity. Ductal NOS was the most common histological subtype accounting for 
88.5% of all cases. We also observed apocrine, atypical medullary and mucinous 
carcinomas. The average tumour size was 25.1mm (T2) and almost 60% (30/52) of the 
cases had regional lymph node metastases at the time of diagnosis.   
 
Table 13 Clinico-pathologic characteristics of cohort 
 Number Percentage 
Patients (all female) 52 100 
Age  
  Range 
  ≤40 










  Ductal 
  Apocrine 
  Atypical medullary 












  1 
  2 
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All of the patients received varied combinations of locoregional and/or systemic therapy. A 
summary is shown in table 14. Treatment was selected based to individual patient and 
tumour characteristics. Partial mastectomy with sentinel lymph node biopsy was the most 
frequent surgical procedure performed and 75% of the patients received post-
surgery/adjuvant radiotherapy. Anthracycline based regimens were the most frequently 
administered neo/adjuvant systemic treatments (Table 15). Forty-six (88.5%) patients 
received doxorubicin or epirubicin either as monotherapy or more frequently in 
combination with other agents.  Two patients received adjuvant tamoxifen. Three patients 
did not receive any chemotherapy and 7 patients did not undergo any surgical procedure for 
varied reasons (i.e. contraindications due to comorbidities, patient refusal of surgical 
treatment, patients lost to follow-up during the course of neoadjuvant therapy). 
Nine (47.4%) of the 19 patients that underwent neoadjuvant chemotherapy had pathologic 
complete responses. These patients all were treated using AC-T regimen. 
 
Table 14 Treatment given to patients with TNBC 
Type of treatment N=52  Percentage 
Neoadjuvant chemotherapy 
   Yes 








    Partial ME with SN biopsy 
    Partial ME with AD 
    ME with AD  












   Yes 








   Neoadjuvant 
   Adjuvant  


















Agent/Regimen   
AC-T   13 14 
FEC      2 4 
CMF     0 1 
XeNA   0 3 
AC        0 8 
AT        0 1 
A         3 0 
T          1 0 
T + carboplatin + bevacizumab - 1 
Tamoxifen - 2 
None   - - 
Abbreviations: A= Doxorubicin; AC= Doxorubicin Cyclophosphamide; AT= Doxorubicin Taxane; AC-
T= Doxorubicin Cyclophosphamide plus Taxane; CMF= Cyclophosphamide Methotrexate 
Fluorouracil; FEC= Fluorouracil Epirubicine Cyclophosphamide; FEC= Fluorouracil Epirubicine 






















The average duration of follow-up was 58 months (range: 3-96 months, median: 60 
months). At the end of the follow-up period 39/52  (75%) patients had no sign of residual 
breast carcinoma. 2 patients developed metachronous breast carcinoma in the contralateral 
breast 16 and 83 months after the primary diagnosis (Tables 16-17). The patients were aged 
70 and 51 years respectively, at the time of the first breast cancer diagnosis. The younger 
patient, who was discovered to be a carrier of a BRCA mutation, was completely disease 
free at the end of the follow-up period.  
Two of the 52 patients had locoregional residual breast disease at the end of the follow-up 
period. These women were lost to follow-up after 6 and 3 months respectively thus the true 
clinical behaviour of their disease remains unknown. Eight of the 52 (15.4%) patients 
developed distant metastasis, all within 37 months of initial diagnosis (average: 21 months, 
range: 12-37 months) (Table 18). All but one of the patients that developed distant 
metastases had lymph node involvement at the time of diagnosis. The only patient with 
pN0 cancer at diagnosis that developed distant metastasis had a pT2 grade 3 atypical 
medullary carcinoma.  
The most frequent metastatic sites were the lung (in 3/8 patients), bone (in 3/8 patients), 
brain (in 3/8 patients), and lymph nodes (in 3/8 patients). Other locations for metastatic 
deposits were the liver (2/8), pleura (2/8), and meninges (1/8).  One of the patients that 
developed lung and brain metastasis was alive and disease-free 67 months after diagnosis. 
Two patients died as a result of complications of metastatic disease 22 and 36 months after 
diagnosis. Clinico-pathologic characteristics of cases that developed distant metastasis are 
shown in table 16.  Two other patients died, both 3 months after primary diagnosis, of 
possible complications of treatment. The last death that occurred in our cohort was as a 
result of generalization of a non-breast (pancreatic) malignancy 60 months after diagnosis 







Table 16 Outcomes of all patients in cohort 
 N=52* % 
Outcomes   
Disease free 39  75.0 
Locoregional residual disease   2  3.8 
Recurrence 2  3.8 
Distant metastasis 8  15.4 
Death 
  TNBC related 







Abbreviation: TNBC= triple negative breast cancer 
*There is an overlap in outcomes; one patient that developed distant metastases and another that had a 
recurrence were both disease-free at the end of the follow up period. Two patients that developed 
distant metastases died during the follow up period. 
 
Table 17 Treatment and outcomes  




Disease free (%) 
N=39 
Type of treatment    
Neoadjuvant chemotherapy 
   Yes 











    Partial ME with SN biopsy 
    Partial ME with AD 
    ME with AD  

















   Yes 











   Neoadjuvant 
   Adjuvant  

































56 Ductal  Luminal 
progenitor 
IIB Moderate  3 2.75 Bone, 
subclavian 
lymph nodes 
50 Ductal  Luminal 
progenitor 
IIB Moderate  4 3.90 Lung, brain 
28 Ductal  Luminal 
progenitor 





70 Ductal  Luminal 
progenitor 
IIIC Poor  8 3.30 Brain 
60 Ductal  Luminal 
progenitor 
IIA Moderate  4 3.60 Liver, bone, 
pleura 
57 Ductal  Luminal 
progenitor 
IIB Moderate  6 2.20 Lung, brain 




IIA Moderate  6 3.49 Pleura 
67 Ductal  Luminal 
progenitor 




Abbreviations: EGFR= epidermal growth factor receptor; Immuno.= immunophenotypic; NPI= 







Traditional prognostic markers 
 
Of the traditional prognostic markers (Table 19), we found that NPI (modified) was the best 
at identifying tumours that were unlikely to metastasize. The association between NPI and 
development of distant metastasis was statistically significant (p=0.036). TNM staging was 
better than lymph node stage or tumour size alone (p=0.183 and p=0.242 respectively) for 
identifying tumours likely to metastasize.  Although none of the TNM stage I tumours 
metastasized during the follow up period, the finding was not statistically significant 
(p=0.124).  
Interestingly p53 positivity appeared to be more frequent in non-metastasizing rather than 
in metastasizing tumours (68.2% vs. 37.5%). This finding however fell short of being 
statistically significant (p=0.097).  There was no relationship between tumour grade and 


























Table 19 Traditional prognostic markers in metastasizing and non-metastasizing tumours 
 Metastasis (%) 
N=8 
No Metastasis (%) 
N=44 
P-value 
Lymph node stage 
 0 (22) 
 1 (17) 
 2 (10) 














 1 (21) 
 2 (20) 
 3 (7) 














 1 (15) 
 2 (25) 












  2 (10) 









 NPI (modified) 
  Good prognosis (18) 
  Moderate prognosis (24) 












  Negative (19) 























We observed marked heterogeneity in the morphology of our sample. Most of the tumours 
(46/52) were classified as invasive ductal NOS carcinomas. There were 3/52 (5.8%) 
apocrine carcinomas (Fig. 8), 2/52 (3.8%) atypical medullary carcinomas (Fig. 9) and 1/52 
(1.9%) mucinous carcinoma (Fig. 10). Even within the ductal carcinoma group morphology 
ranged from almost dedifferentiated tumours with bizarre nuclei and syncytial growth 
pattern to tumours with 100% tubule formation and only moderate nuclear atypia (Figs. 11-
15). 
One feature that was observed in a majority of our cases was intratumoural heterogeneity. 
This was a feature frequently observed in tumours with predominantly solid/syncytial 
architecture in which we detected a spindle cell sub-population. Intratumoural 
morphological heterogeneity was frequently accompanied by non-uniform expression of 
the molecular markers we investigated. 
In our group of tumours we observed all tumour characteristics that have been described as 
being typical for TNBCs and/or BLBCs i.e. solid architecture, pushing borders, ribbon-like 
architecture, central acellular zone, geographic necrosis, high nuclear atypia and presence 
of lymphoplasmacytic infiltrate. Expression of basal markers was not limited to tumours 
with typical basal morphology.  
None of the morphological characteristics we assessed showed a statistically significant 
association with development of distant metastasis (Table 20).  However, none of the 3 



















 1 (3) 
 2 (8) 
 3 (33) 














 Pushing  (10) 










 Non-syncytial (35) 










 Absent (33) 










  Minimal (8) 
  Moderate (37) 












Central acellular zone 
 Absent (35) 










 Absent (26) 
 Focal (9) 












 Minimal (14) 
 Moderate (31) 
 Abundant (6) 














 Absent (41) 













































































Figure 11 Invasive ductal carcinoma NOS with vesicular nuclei and prominent nucleoli 
Figure 12 Invasive ductal carcinoma NOS with minimal nuclear atypia 
Figure 13 Invasive ductal carcinoma NOS with bizarre pleomorphic nuclei 




Figure 15 Tubule formation in TNBC 
 
 




























Figure 17 High grade DCIS with microinvasion in TNBC 




Of all the molecular markers we investigated, p-cadherin was the most frequently expressed 
in our sample of TNBCs. All of the tumours showed some degree of p-cadherin positivity 
(Table 21). Intensity of staining was relatively uniform throughout the tumour tissue. Most 
of the tumours showed strong to moderate p-cadherin positivity. Twenty-six tumours 
(50.0%) were strongly positive for p-cadherin, 19/52 (36.5%) showed moderate staining 
intensity and only 7/52 (13.5%) cases were weakly positive (Figs. 19-21). We could not 
find any statistically significant association between intensity of p-cadherin staining and 
tumour grade (p=0.441), lymph node status (p=0.686), development of distant metastasis 
(p=0.230) or final outcome (p=0.245). 
 
Table 21 P-cadherin expression and selected tumour characteristics/clinical behaviour 
Intensity of p-cadherin staining 








  2 (10) 













  Positive (30) 













 No (44) 












Final outcome  
  Good (39) 
















Figure 19 Weak p-cadherin staining 
 
Figure 20 Moderate p-cadherin staining 
  






P63 positivity was not a common feature of our samples (Table 22). Twenty-three (44.2%) 
were completely negative, 23/52 (44.2%) showed nuclear positivity in <10% tumour cells, 
4/52 (7.7%) showed positive nuclear staining in ≥10% but less than 50% of tumour cells, 
and in only 2 cases (3.8%), over 50% of the tumour cells showed p63 positivity (Figs. 22-
23). In the tumours with less than 10% positive tumour cells it was sometimes uncertain as 
to whether we were observing true tumour positivity or merely entrapped myoepithelial 
cells from residual breast tissue. One p63+ of the tumours was an apocrine carcinoma, the 
rest were ductal NOS carcinomas. Only 2 of the p63 positive tumours did not show 
concurrent p53 expression. Patients with <10% p63 positive tumour cells were less likely 
than those with ≥10% positively stained cells to have bad outcome (19.6% vs. 66.7% 
respectively).  We found no statistically significant difference between p63+ and p63- 
tumours in terms of tumour grade (p=0.535), lymph node status (p=0.701) or development 
of distant metastasis (0.295).   
Table 22 p63 expression and selected tumour characteristics/clinical behaviour 











  2 (10) 
















Lymph node status 
  Positive (30) 
















  No (44) 















Final outcome  
  Good (39) 

















Figure 22 Weak focal p63 positivity 
 
 






CD10 was the least frequently expressed marker in our group of TNBCs (Table 23). 
Although CD10 positivity was not a common feature of TNBC tumour cells, it was 
frequently seen in the tumour stroma (Fig. 24). Almost 70% (36/52) of our cases were 
completely negative for CD10. Staining in <10% tumour cells was observed in 15.4% 
(8/52), CD10 positivity in ≥10% tumour cell (but less than in 50%) was seen in 7.7% of 
cases. Only 4/52 (7.7%) tumours had ≥50% CD10 positive tumour cells (Fig. 25). Patients 
with CD10 negative tumours were less likely to have bad outcome than patients with 
tumours that showed any degree of CD10 positivity (16.7% vs. 43.7% respectively) 
however this finding did not achieve statistical significance (p=0.084). We also found no 
statistically significant link between CD10 expression and tumour grade (p=0.810), lymph 
node status (p=0.653) or development of distant metastasis (p=0.215). 
 
Table 23 CD10 expression and selected tumour characteristics/clinical behaviour 











  2 (10) 















Lymph node status 
  Positive (30) 

















  No (44) 















Final outcome  
  Good (39) 



















Figure 24 Strong stromal CD10 positivity, tumour cells completely CD10 negative 
 
 





CK5/6 expression was observed in 78.8% (41/52) of our cases (Table 24) (Fig. 26). 
Uniform, diffuse staining however was a feature of only 13.5% (7/52) of cases (Fig. 27). 
We could not demonstrate a statistically significant association between degree of 
intratumoural CK5/6 expression and tumour grade (p=0.308), lymph node status (p=0.425), 
development of distant metastasis (p=0.759) or final outcome (0.557).   
 
Table 24 CK5/6 expression and selected tumour characteristics/clinical behaviour 











  2 (10) 















Lymph node status  
  Positive (30) 
















  No (44) 















Final outcome  
  Good (39) 























Figure 26 Partial CK5/6 staining 
 
 





HMW staining was a common feature in our sample (Figs. 28-30). Intratumoural 
heterogeneity of expression was not uncommon. Only 3/52 (5.8%) tumours were negative 
for this marker (Table 25). These tumours were all grade 3 ductal NOS carcinomas. None 
of the patients with HMW negative carcinomas developed distant metastasis; they all had 
good outcomes at the end of the follow up period however these findings were not 
statistically significant (p=0.715, p=0.762 respectively). We also observed no statistically 
significant association between HWM staining and tumour grade (p=0.806) or lymph node 
status (p=0.659) 
 
Table 25 HMW expression and selected tumour characteristics/clinical behaviour 











  2 (10) 
















Lymph node status 
  Positive (30) 
















  No (44) 















Final outcome  
  Good (39) 




















Figure 28 Weak HMW staining 
 
Figure 29 Heterogeneous HMW staining 
 
 





Forty-six (88.5%) of the 52 tumours in our sample showed some degree of EGFR 
expression (Table 26) (Figs. 31 and 32). We found no statistically significant relationship 
between EGFR score and tumour grade (p=0.379), lymph node status (p=0.531), 
development of distant metastasis (p=0.899) or final outcome (p=0.680). 
 
Table 26 EGFR score and selected tumour characteristics/clinical behaviour 











  2 (10) 
















Lymph node status 
  Positive (30) 
















  No (44) 















Final outcome  
  Good (39) 























Figure 32 Strong diffuse EGFR staining (EGFR score 12)  
 
Figure 31 Weak to moderate incomplete EGFR staining (EGFR score 4) 
80 
 
EGFR (dual ISH) 
Details of gene copy number changes are shown in table 27. Almost all of the tumours had 
normal G:C ratios (Figs. 33-34), only one tumour showed EGFR gene amplification 
(G:C=4.05) (Fig. 35). The EGFR amplified tumour was a grade 3 ductal carcinoma in a 42 
year old woman.  Eight tumours had ≥4 EGFR gene copies per cell (table 28). None of the 
tumours with ≥4 EGFR gene copies per cell metastasized during the course of the follow-
up period. Three of them were grade 3 ductal carcinomas NOS, 2/8 grade 3 apocrine 
carcinomas, 1/8 medullary carcinoma, 1/8 mucinous carcinoma and 1/8 was a grade 2 
ductal carcinoma NOS. Gene copy number showed a statistically significant association 
with final outcome (p=0.036); high gene copy number (≥4 copies per cell) was associated 
with positive outcome. There were no statistically significant relationships observed 
between gene copy number and tumour grade (p=0.898), lymph node status (p=0.863) or 
development of distant metastasis (p=0.211) 
Table 27 EGFR gene copy number per cell and selected tumour characteristics/clinical behaviour 









  2 (10) 













Lymph node status 
  Positive (30) 














  No (44) 













Final outcome  
  Good (39) 















Table 28 Clinico-pathologic characteristics of tumours with high (≥4) EGFR gene copy numbers 




NPI EGFR score EGFR gene 
copy number 
G:C 
46 Ductal 3 IIA Moderate 6 5.00 1.51 
83 Apocrine  3 IIIA Poor 2 4.14 1.01 
48 Atypical 
medullary 
3 I Good 4 4.26 1.65 
45 Ductal 3 I Good 9 4.19 1.06 
55 Apocrine 3 IIIA Poor 12 4.09 1.03 
84 Mucinous  2 IIA Good 6 4.30 1.30 
42 Ductal  3 IIA Moderate 12 12.77 4.05 
73 Ductal  2 IIA Good 12 4.04 0.91 
Abbreviations: G:C= EGFR gene-chromosome 7 ratio; NPI= Nottingham Prognostic Index; TNM= 




















































Only 2 (3.8%) tumours showed complete loss of CK18 (Table 29). Both tumours were 
grade 3 ductal NOS tumours. Staining intensity and extent varied from weak partial to 
strong complete positivity in the rest of the tumours (Figs. 36-37). Neither of the patients 
with CK18 negative tumours developed distant metastasis however this finding was not 
statistically significant. We also found no statistically significant association between CK18 
staining and tumour grade (p=0.359), lymph node status (p=0.781) or final outcome 
(p=1.00). 
 





 CK18 staining 








  2 (10) 













Lymph node status 
  Positive (30) 













  No (44) 












Final outcome  
  Good (39) 














Figure 36 Partial loss of CK18 staining  
 
 





All of the tumours expressed at least one of the basal markers. Based on our predefined 
criteria, 50/52 tumours showed luminal progenitor (luminal and basal) differentiation 
(Table 30). The remaining 2 tumours showed pure/’true’ basal differentiation with complete 
loss of CK18 expression. According to Nielsen’s criteria (TNBC with CK5/6 and/or 
EGFR+), 50/52 of our TNBC were basal-like. 
 
Table 30 Morphological and immunophenotypic subtypes  







Ductal NOS 0 44 (88.0) 2 (100.0) 
Apocrine 0 3 (6.0) 0 (0.0) 
Atypical 
medullary 
0 2 (4.0) 0 (0.0) 




















Taken as a whole, patients with triple negative breast carcinomas have worse prognosis 
than those with hormone receptor positive tumours or appropriately selected HER2-positive 
tumours that receive HER2 targeted therapy. The group however is clearly biologically 
heterogeneous as the patients have divergent outcomes regardless of treatment or known 
prognostic factors including stage. Some patients with triple negative breast carcinomas 
develop generalized disease resulting in death within two years of diagnosis while others 
with advanced carcinomas remain disease free for over 6 years after standard oncological 
therapy. 
Clearly, there are important underlying differences in the nature of the entities comprising 
the group demonstrated by the observation of different outcomes in patients with age, stage 
and grade matched tumours that received identical treatment. Identifying the patients with 
truly aggressive disease would help to modify and optimize their management. In addition, 
providing patients with more accurate information on their prognosis earlier on in the 
course of the disease would likely improve their ability to cope with their illness and its 
treatment. 
 
Results from studies on triple negative carcinomas with emphasis on basal-like carcinomas 
are difficult to compound and compare because of the lack of a standard definition of triple 
negativity. Some investigators have defined triple negativity as positive ER and PR nuclear 
staining in <10% of tumour cells some use 5% as the threshold while other more stringent 
investigators use 1%. We excluded from our definition of triple negative all tumours that 
showed any staining for hormone receptors as studies show that even tumours with minimal 
hormone receptor expression could respond to hormonal therapy (159). By using such tight 
boundaries in our definition, we ensured that only the tumours that are most likely to be 
truly biologically distinct from hormone receptor positive carcinomas were included in the 
study.  
 
Our TNBC patients differed from the non-TNBC patients in terms of age and tumour 
features. The TNBC patients were younger than the HR+ patients and the same age as 
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HER2+ patients. The TN group had the highest proportion of poorly differentiated tumours. 
Our TNBCs were not associated with higher stage when compared with figures for breast 
carcinoma in general taken from the Czech Cancer Registry. 
 
TNBC and lymph node metastasis 
Lymph node metastasis is the most important independent prognostic factor for patients 
with breast carcinoma (15). Approximately 40% of women with breast cancer have regional 
lymph node involvement at the time of diagnosis. Despite the fact that lymph node status 
alone is the most important independent prognostic factor in women with breast cancer, 
approximately 25% of patients with node-negative disease die from metastatic disease and 
a similar proportion of patients with node-positive disease do not develop distant 
metastases. Thus negative lymph node status alone does not automatically suggest good 
prognosis (73). Node-positive disease is associated with an overall mortality rate of 
approximately 20% (73). The greater the number of nodes involved, the worse the 
prognosis (42). Despite the fact that relationship between TNBC and prevalence of lymph 
node metastasis is unclear, the accepted theory is that TNBC seems to spread to axillary 
lymph nodes less frequently than non-TNBC (43). Almost 60% of our TNBC cases had 
lymph node metastasis at the time of diagnosis. Of our 30 node-positive patients, 7 (23.3%) 
went on to develop distant metastasis during the follow up period. On the other hand, only 
one of the 22 node-negative patients (4.5%) developed distant metastasis. Negative lymph 
node status was thus a useful parameter for identifying tumours less likely to metastasize. 
However, we found no significant association between lymph node stage and metastasis 
amongst the lymph node positive cases.  
 
TNBC and NPI 
NPI combines time dependent (tumour size and lymph node metastases) and tumour 
dependent (histological grade) characteristics (42). Using NPI, 34.6% (18/52) of our 
TNBCs had good prognosis, 46.2% (24/52) had moderate prognosis and 19.2% (10/52) had 
poor prognosis. None of the patients with good prognosis developed distant metastases, 
20.8% of the patients with moderate prognosis developed metastases and 30% of those with 
poor prognosis developed metastases. NPI was thus a useful tool in stratifying risk of 
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metastasis. The association between NPI and outcome was statistically significant 
(p=0.036). The finding suggests that tumour burden and histological grade may play a more 
important role in outcome of TNBC than other tumour characteristics.  
 
 
Morphology of TNBC 
It seems that TNBCs as a group of carcinomas are as morphologically heterogeneous as 
breast carcinomas in general. We observed a wide range of morphologic pictures even 
within the group of ductal NOS carcinomas. One common morphologic feature of the 
ductal NOS carcinomas was the presence of a population of spindled cells.  
None of the morphological tumour characteristics we studied was significantly associated 
with development of distant metastasis. As all of our tumours expressed basal markers, we 
could not compare morphological characteristics in basal versus non-basal TNBCs.  
Half (4/8) of the tumours that showed high EGFR copy numbers were ‘special’ histological 
types of breast cancer (apocrine, mucinous and atypical medullary breast carcinomas). This 
suggests that morphology is an important manifestation of breast tumour biology and thus 
could play a significant role in patient selection for various types of targeted therapy.  Reis-
Filho et al also showed a link between breast tumour morphology and EGFR changes. They 
observed frequent overexpression of EGFR and EGFR gene amplification in metaplastic 
breast carcinomas and suggested that some patients with metaplastic breast carcinomas 
might benefit from EGFR targeted therapy (160).   
 
TNBC, basal-like breast cancer and other immunophenotypic subtypes  
Jumppanen et al wrote ‘Apart from hypothesis-generating scientific research, a breast 
cancer classification should correlate with clinical outcome of patients or predict efficacy 
to therapy’ (121). We were interested in seeing whether or not there was any clinical value 
in sub-classifying TNBCs as basal or non-basal like with the aim of possibly expanding our 
panel of standard prognostic and predictive markers in order to provide more precise 
information for clinicians and patients alike.  
We did not find identification of the basal-like phenotype useful in prognostic stratification 
of TNBC. This was because according to the ‘gold standard’ Nielsen definition (TNBC 
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with CK5/6 and/or EGFR+), 96.2% of our cases were basal-like, with only 2 tumours being 
non-basal. Even these two tumours showed expression of other markers of basal 
differentiation (i.e. p-cadherin/p63 and p-cadherin/HMW, respectively).  
Many authors have repeatedly emphasized that not all TNBCs are basal-like (7, 101, 161); 
our findings rather suggest the opposite, perhaps as a result of our strict 
immunohistochemical definition of triple negativity. 
Silver et al also reported that using stricter criteria for defining triple negativity (less than 
1% nuclear staining for oestrogen and progesterone receptors and HER2 score 0 or 1+ or 
HER nonamplified by FISH) reliably predicted classification of breast carcinomas into the 
basal-like subtype by hierarchal cluster analysis of the intrinsic genes (99).  
 
One problem with the term ‘basal-like’ is that it implies myoepithelial-like as well as 
progenitor cell-like. By definition, it includes tumours that resemble basally-located 
myoepithelial cells and the breast progenitor cells which are not limited to any anatomical 
location in the TDLU (2). Rakha et al classified breast carcinomas as non-basal 
carcinomas, tumours with basal phenotype (CK5/6 and/or CK14+) and tumours with 
myoepithelial phenotype (p63 and/or SMA+) (162). They found that breast cancers with 
basal and myoepithelial phenotype are distinct groups that share some common 
morphological features and an association with poor prognosis.    
In our opinion the term basal-like is too ambiguous for use in daily practice and provides 
less clinical information than the triple negative designation. While both TNBC and BLBC 
are known to be heterogeneous groups generally associated with poor prognosis, unlike 
BLBC, the TNBC designation provides predictive information useful for directing patient 
management.  
 
Figure 38 shows our proposal for immunophenotypic classification of TNBC. Not 
surprisingly, none of our tumours showed exclusive luminal marker expression. All of them 
fell into either the ‘true’ basal (2/52) category or the dual/luminal progenitor (50/52) 
category.   
Our finding of co-expression of luminal marker CK18 with basal markers (and minimal 
expression of p63 and CD10) in the majority of our cases is in support of the hypothesis 
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that the so called basal-like tumours, which form the vast majority of TNBCs, may arise 
from luminal progenitor cells rather than stem cells or myoepithelial progenitor cells (4).   
 
The clinical significance of subtypization in TNBC based on cell of origin is questionable. 
In our sample, identification of immunophenotypic subtypes with focus on identification of 
















TNBC and BRCA mutations 
Three of the patients in our sample were discovered to be carriers of BRCA mutations (the 
BRCA statuses of the rest of the cohort were unknown). All of them had stage IIA grade 3 
ductal carcinomas with varied expression patterns of all the investigated molecular markers. 
All of them had surgical treatment and underwent AC-T chemotherapeutic regimen. Two of 
them had adjuvant radiotherapy. Although one patient developed metachronous breast 
cancer in her contralateral breast, all three of them were disease free at the end of the 
follow-up period (average: 75 months; range: 56-74 months).  
 
 
Figure 38 Immunophenotypic classification of TNBC 













TNBC and response to therapy 
Nine of the 19 patients that received neoadjuvant chemotherapy achieved pCR. AC-T 
chemotherapeutic regimen was administered in all the 9 cases. All nine of them underwent 
partial mastectomy with axillary dissection and all but one had adjuvant radiotherapy. All of 
the patients that achieved pCR remained disease free at the end of the follow up period 
(average: 83 months; range: 54-98 months). These patients showed varied clinico-
pathologic characteristics and varied expression patterns of the molecular markers we 
investigated. We found no single unifying characteristic amongst all the patients that 
achieved pCR to distinguish them from the other patients that underwent neoadjuvant 
chemotherapy but did not have pCR.  
We note that 2 of the patients that underwent neoadjuvant chemotherapy and ended up not 
having surgical treatment were without signs of disease progression at the end of the follow 
up period (79 and 46 months, respectively). Both patients had stage IIIA disease and both 
underwent radiotherapy.  
Choice of treatment appeared not to play a big role in development of distant metastasis or 
patient outcome.  
 
Predicting outcome in TNBC 
Rakha et al reported that time dependent pathological factors are the most useful in 
outcome prediction (123). In general, our findings are in accordance with theirs as in our 
sample, NPI was statistically significantly associated with development of distant 
metastasis. It is important to note that NPI, which also takes into account tumour 
histological grade, was a better predictor that the purely time dependent TNM stage (Fig. 
39). P53 expression was higher in patients that did not develop distant metastasis (though 
not statistically significant; p=0.097). This could be a reflection of better response of p53 
expressing TNBCs to chemotherapy as suggested by Bidard et al (64). 
EGFR gene copy number was the only molecular characteristic we observed that showed a 
statistically significant, however limited, ability to predict outcome. All the TNBCs with 4 
and higher EGFR gene copies per cell showed no sign of progression at the end of the 
follow up period. None of the other molecular markers we investigated were able to stratify 






Anti-EGFR therapy for TNBC 
Though 88.5% of our sample showed EGFR expression, amplification of the gene was seen 
in only one case. Our finding of rare EGFR gene amplification in TNBC was also reported 
by Nakajima et al in their study of 84 TNBCs (148). None of their tumours showed EGFR 
amplification. In addition to IHC and in dual in situ hybridization, they also performed 
EGFR gene mutation analysis. No EGFR gene activating mutations were found. Jacot et al 
also found no EGFR-activating mutations in their group of 229 TNBCs (163); neither did 
Uramoto et al in their PCR-based study on 84 breast carcinomas, 45% of which were ER 
negative. They concluded that EGFR tyrosine kinase inhibitors are unlikely to provide any 
benefit for Japanese breast cancer patients (164). 
Lv et al on the other hand observed a higher incidence of EGFR gene amplification in their 
set of 139 unselected breast carcinomas; positivity in 33.1% of all cases (146). They did, 
however, also report a low rate of EGFR mutations (in 1.4% of all cases) and concluded 
 
Metastasis 
Time dependent factors 
- TNM stage  
Tumour dependent 
factors  




Figure 39 Factors leading to metastasis development 
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that EGFR mutations should not be used in trials testing anti-EGFR therapy in breast 
cancer.  
Based on a study comparing 40 patients with TNBC to 158 patients with non-TNBC, Tang 
et al proposed that EGFR overexpression predicts better response to neoadjuvant 
chemotherapy in TNBC as EGFR overexpression was significantly associated with pCR in 
these patients (165).   
 
  
Pitchard noted that an ideal target for targeted therapy should have the following 
characteristics; 
 It should be a critical driver of the malignancy when it is abnormal 
 It is associated with poor outcomes 
 It can be successfully targeted by an agent without significant toxicity that acts 
though a well understood mechanism (166) 
 
We were not able to demonstrate that EGFR changes are associated with poor outcome, 
neither are we certain that EGFR abnormalities are critical drivers of TNBC. This makes us 
question the suitability of EGFR as a therapeutic target for TNBC, certainly not for all 
subtypes of TNBC. The observation of a statistically significant link between high EGFR 
copy number and good outcome makes us further doubt that blocking the action of EGFR 
in TNBCs will produce favourable results. 
After a phase II trial testing cetuximab in patients with metastatic TNBC Carey et al 
concluded that ‘therapy targeting growth factor pathways in this subtype (TNBC) may 
require a far better understanding of the pathways maintaining EGFR activity’ (92). Our 
findings put us in agreement with this statement. The role of EGFR in breast cancer appears 
to be highly complex and using anti-EGFR agents for treatment of TNBC at this point 









 Axillary lymph node involvement is a relatively common feature of TNBC 
 Time dependent factors are significant predictors of prognosis in TNBC 
 All TNBCs express at least 1 basal marker and could thus be considered ‘basal-like’ 
 Complete loss of CK18 is a rare feature of TNBC  
 EGFR gene amplification is a rare event in TNBC 
 High EGFR gene copy numbers (≥4 copies per cell) may be associated with 
favourable outcome in TNBC.   
 
We observed a wide variation in the clinical behaviour of different cases of TNBC showing 
that assigning a blanket ‘poor’ prognosis in all cases is misleading and could result in 
overtreatment of patients that may not need aggressive adjuvant therapy. Based on our 
findings, we recommend a combinatorial approach to prognostication in TNBC using 
simple tools such as NPI, which proved to be useful in the stratification of patients into 
prognostic groups.   
Identification of the basal-like phenotype using varied IHC definitions, in TNBC, had no 
clinical impact. Also, as the vast majority of our cohort showed co-expression of luminal 
marker CK18 and markers of basal differentiation, we are in favour of adopting the term 
luminal progenitor-like to better describe this group of TNBCs in order to differentiate 
them from carcinomas with  (basally located) myoepithelial differentiation.  
The clinical significance of molecular classification based on cell of origin is doubtful and 
limited, partially because of the significant overlap in protein expression amongst the cell 
types comprising the TDLU. The findings of this study put us in agreement with Rahka et 
al who observed that the concept of tumour differentiation rather than histiogenesis is more 
appropriate in the era of tailored therapies and predictive classification systems (119). It is 
likely that molecular profiling will play an increasingly important role in breast cancer 
diagnosis and management in the future, however, like Hanby (167) we believe the 
importance of morphology in tumour assessment should not be underestimated.  
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The unexpected finding of good outcome in patients with carcinomas showing high EGFR 
copy number calls to question the suitability of anti-EGFR treatment in patients with 
TNBC. Though our study was limited by its size and its retrospective nature, we found 
nothing to indicate that EGFR was a driver of aggressive behaviour. We were thus unable to 
provide evidence supporting the use of anti-EGFR therapy in unselected cases of TNBC. 
We did, however, discover that EGFR gene copy number may be of use in determining 
prognosis in TNBC.  High EGFR gene copy number could be an independent marker of 
good outcome in TNBC.  
The molecular markers and morphological characteristics we investigated were not useful 
in providing a basis for clinically relevant classification of TNBC. Instead, we confirmed 
the importance of simple combinatorial prognostic tools like the Nottingham Prognostic 
Index. 
We propose that high EGFR copy number should be further investigated as a potential 
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9. Figure legends 
 
Tables 
Table 1 WHO histological classification of breast carcinoma (15) p. 14 
Table 2 Assessment of histological grade in breast carcinomas (15) p. 15 
Table 3 TNM classification for breast cancer p. 16 
Table 4 Anatomic stage (prognostic) groups p. 18 
Table 5 Prognostic groups of Nottingham Prognostic Index (42) p. 22 
Table 6 Components of IRS system for immunohistochemical detection of oestrogen and 
progesterone receptors in breast cancer (48) p. 23 
Table 7 HER2 testing in breast cancer (49) p. 24  
Table 8 Preferred agents for adjuvant chemotherapy in different breast cancer subtypes (69) 
p. 29 
Table 9 Molecular marker expression of various breast TDLU cell types p. 43 
Table 10 Details of antibodies used p. 47  
Table 11 Staining for technique for p-cadherin p. 47 
Table 12 Age and immunophenotype of all patients diagnosed with breast cancer at the 
Fingerland Department of Pathology (2005-2008) p. 51 
Table 13 Clinico-pathologic characteristics of cohort p. 53 
Table 14 Treatment given to patients with TNBC p. 54 
Table 15 Chemotherapy agents and regimens administered to TNBC patients p. 55 
Table 16 Outcomes of all patients in sample p. 57 
Table 17 Treatment and outcomes p. 57 
Table 18 Characteristics of metastasizing tumours p. 58 
Table 19 Traditional prognostic markers in metastasizing and non-metastasizing tumours p. 
60 
Table 20 Morphological features of metastasizing and non-metastasizing tumours p. 62 
Table 21 P-cadherin expression and selected tumour characteristics/clinical behaviour p. 68 
Table 22 p63 expression and selected tumour characteristics/clinical behaviour p. 70 
Table 23 CD10 expression and selected tumour characteristics/clinical behaviour p. 72 
Table 24 CK5/6 expression and selected tumour characteristics/clinical behaviour p. 74 
117 
 
Table 25 CK18 expression and selected tumour characteristics/clinical behaviour p. 76 
Table 26 EGFR score and selected tumour characteristics/clinical behaviour p. 78 
Table 27 EGFR gene copy number per cell and selected tumour characteristics/clinical 
behaviour p. 80 
Table 28 Clinico-pathologic characteristics of tumours with high (≥4) EGFR gene copy 
numbers p. 81 
Table 29 HMW expression and selected clinic-pathologic features p. 84 
Table 30 Morphological and immunophenotypic subtypes p. 86 
 
Figures 
Figure 1 Normal breast TDLU with 2 distinct layers of cells lining tubular structures p. 9 
Figure 2 CK18 staining cytoplasm of luminal cells of TDLU p. 9 
Figure 3 CD10 staining basally located cells of TDLU p. 10 
Figure 4 p63 staining nuclei of basally located cells of TDLU p. 10  
Figure 5 Stage distribution for women diagnosed with breast cancer in the Czech Republic 
(17) p. 19 
Figure 6 Immunohistochemical phenotypes of intrinsic breast cancer subtypes (10, 35, 39) 
p. 21  
Figure 7 Histological grade and immunophenotype of all breast carcinomas diagnosed in 
2005-2008 p. 52 
Figure 8 Apocrine TNBC p. 63 
Figure 9 Atypical medullary TNBC p. 63 
Figure 10 Mucinous TNBC p. 64 
Figure 11 Invasive ductal carcinoma NOS with vesicular nuclei and prominent nucleoli p. 
65 
Figure 12 Invasive ductal carcinoma NOS with minimal nuclear atypia p. 65 
Figure 13 Invasive ductal carcinoma NOS with bizarre pleomorphic nuclei p. 65 
Figure 14 Invasive ductal carcinoma NOS with spindle cell subpopulation p. 65 
Figure 15 Tubule formation in TNBC p. 66 
Figure 16 Solid architecture in TNBC p. 66 
Figure 17 High grade DCIS with microinvasion in TNBC p. 67 
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Figure 18 Lymphangioinvasion in triple negative (apocrine) breast carcinoma p. 67 
Figure 19 Weak p-cadherin staining p. 69 
Figure 20 Moderate p-cadherin staining p. 69 
Figure 21 Strong p-cadherin staining p. 69 
Figure 22 Weak focal p63 positivity p. 71 
Figure 23 Strong diffuse p63 positivity p. 71 
Figure 24 Strong stromal CD10 positivity, tumour cells completely CD10 negative p. 73 
Figure 25 CD10 positivity of >50% of tumour cells p. 73 
Figure 26 Partial CK5/6 staining p. 75  
Figure 27 Strong complete CK5/6 staining p. 75 
Figure 28 Weak HMW staining p. 77 
Figure 29 Heterogeneous HMW staining p. 77 
Figure 30 Strong HMW staining p. 77 
Figure 31 Weak to moderate incomplete EGFR staining (EGFR score 4) p. 79 
Figure 32 Strong diffuse EGFR staining (EGFR score 12) p. 79 
Figure 33 No numerical chromosome 7 or EGFR gene abnormalities (G:C=1.03) p. 82 
Figure 34 Polysomy of chromosome 7 without EGFR gene amplification (G:C=1.01) p. 8  
Figure 35 EGFR gene amplification (G:C=4.09) p. 83 
Figure 36 Partial loss of CK18 staining p. 85 
Figure 37 Normal (complete) CK18 staining p. 85 
Figure 38 Immunophenotypic classification of TNBC p. 91 
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